Azacycloalkane Menin-MLL protein inhibitor as well as pharmaceutical composition and application thereof

By designing a specific structure of Menin-MLL protein inhibitor, the failure and cardiotoxicity of existing drugs in drug-resistant patients is solved, and effective inhibition of Menin-MLL protein and reducing the risk of hERG channel blockade is achieved.

CN118930525APending Publication Date: 2024-11-12SCINNOHUB PHARM CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410573329.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing Menin-MLL protein inhibitors are ineffective in some drug-resistant patients, and the drug has insufficient blocking potential for hERG potassium channels, resulting in an increased risk of cardiotoxicity. It is necessary to develop new compounds that can effectively inhibit Menin-MLL protein interactions. to reduce these risks.

Method used

Provide a Menin-MLL protein interaction inhibitor, which is a compound of a specific structure, including combinations of groups such as R1, R2, R3, X1, X2, X3, X4, etc., optimizes the binding ability to the Menin mutant protein, and Reduce the blocking effect on hERG channels.

Benefits of technology

Effective inhibition of Menin-MLL protein was achieved, especially in drug-resistant patients, which significantly improved the therapeutic effect, while reducing the impact on hERG channels and reducing the risk of cardiotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930525A_ABST
    Figure CN118930525A_ABST
Patent Text Reader

Abstract

The invention provides an aza-cycloalkane Menin-MLL protein inhibitor as shown in a formula (I), a pharmaceutical composition of the aza-cycloalkane Menin-MLL protein inhibitor and application of the aza-cycloalkane Menin-MLL protein inhibitor in preparation of drugs for preventing or treating related diseases caused by interaction with Menin-MLL protein. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an azacycloalkane Menin-MLL protein inhibitor, a pharmaceutical composition thereof, and an application thereof in preparing a drug for preventing or treating diseases related to the interaction with the Menin-MLL protein. Background Art

[0002] MLL (Mixed Lineage Leukemia) protein is a histone methyltransferase, also known as KMT2A (Histone-lysine N-methyltransferase 2A). MLL rearranged (MLL-r) leukemia is caused by the translocation of the 11q23 chromosome locus containing the KMT2A gene. It is known that this chromosomal translocation can produce more than 60 oncogenic fusion proteins - formed by the amino terminus of MLL fused with a variety of different proteins, among which the MLL-AF4 / 9 fusion mutation is the most malignant. MLL-r leukemia accounts for 5% to 10% of acute leukemia in adults and 70% of acute leukemia in infants. Currently, there are limited treatment options, mostly chemotherapy drugs, with poor prognosis and high recurrence.

[0003] Menin is a protein mainly localized in the nucleus. It is encoded by the Multiple Endocrine Neoplasia Type 1 (MEN1) gene and is an important cofactor of the oncogenic MLL-r fusion protein. It has a high affinity with the MLL-r protein. After binding to the MLL-r protein, Menin recruits chromatin modification enzymes such as Dot1L or pTEFb complex, leading to enhanced transcription of genes including HOXA and MEIS1. The abnormal expression of these genes hinders the differentiation of hematopoietic cells and promotes their proliferation. In vitro and in vivo experiments have shown that Menin inhibitors can disrupt the interaction between Menin and MLL-r and specifically lead to growth inhibition and apoptosis of leukemia cells carrying MLL-r mutations (Cancer Cell 36, 660–673). Studies have also found that Menin inhibitors are also effective against leukemias with NPM1 gene mutations, which account for about 20-30% of acute myeloid leukemia patients (Science 367, 586–590).

[0004] Currently, several Menin inhibitors are being studied in phase 1 / 2 clinical trials for patients with relapsed / refractory acute leukemia who carry MLL-r or NPM1 mutations, such as Syndax's SNDX-5613, Kura Oncology's KO-539, and Daichi Sankyo Group's DS-1594b. In a clinical trial called AUGMENT-101, 53% of the 60 evaluable patients responded to the drug, but after the second treatment cycle, some patients developed resistance to SNDX-5613 (Nature 615, 913–919). Further studies have found that these resistant patients have MEN1 gene mutations, which prevent Menin inhibitors from binding well to Menin proteins. Therefore, it is particularly important to develop inhibitors that can bind to Menin mutant proteins, which will also bring hope of cure to these resistant patients.

[0005] In addition, excessive expression of Menin can lead to the blockage of β-cell proliferation, resulting in relatively insufficient insulin secretion. A Menin-MLL inhibitor has been shown to enhance β-cell proliferation, thus providing the possibility of application in the field of diabetes. Currently, one compound, BMF-219, is undergoing phase 2 clinical studies for type 2 diabetes.

[0006] Cardiotoxicity of drugs, especially arrhythmias caused by prolonged QT interval, has become a major issue threatening the safety of public medication, and is also a drug cardiac safety issue that is widely concerned by drug regulatory authorities and new drug research and development companies. The protein product encoded by the hERG gene is a key membrane-bound potassium ion channel in myocardial tissue, which is controlled by membrane potential and regulates the outflow of potassium ions from cells in a gated manner. When the compound binds to the hERG potassium channel, it blocks the outflow of potassium ions and prolongs the repolarization time of myocardial cells, which is reflected in the electrocardiogram as a prolonged QT interval. In drug development, it is extremely important to determine the potential of candidate compounds to block the hERG channel. There is an urgent need to develop compounds that cause minimal blockage of the hERG channel to reduce the risk of clinical medication. Summary of the invention

[0007] One of the purposes of the present application is to provide a Menin-MLL protein interaction inhibitor, which is a compound shown in the following formula I, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof:

[0008] Among them, R is selected from

[0009] L is selected from a covalent bond or CH2;

[0010] X1, X2, X3, X4 are each independently selected from CH2 or CH2CH2;

[0011] R1 is selected from C1-C6 alkyl, C1-C6 haloalkyl, C3-C8 cycloalkyl, 3-8 membered alicyclic group containing 1-2 atoms selected from N, O, S, 5-10 membered aryl, 5-12 membered heteroaryl, -NR3R4, 7-12 membered spirocyclic group containing 0-3 heteroatoms selected from N, O, S;

[0012] Alternatively, R1 may be one or more selected from halogen, C1-C6 alkyl, C1-C6 alkoxy, cyano, -NHCO-(C1-C3 alkyl), -COR x wherein Rx is C1-C6 alkyl, C2-C4 alkenyl or -CH=CHCH2N(CH3)2;

[0013] R2 is selected from H or halogen;

[0014] R3 is selected from H or C1-C3 alkyl; R4 is selected from C1-C3 alkyl or C1-C3 haloalkyl;

[0015] ------ represents possible chemical bonds.

[0016] In certain specific embodiments, the present application provides a compound having a structure shown in the following formula II, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof:

[0017]

[0018] Among them, L, R1, R3, R4, X1, X2, X3, and X4 are defined as before.

[0019] In certain specific embodiments, said L is selected from CH2.

[0020] In certain specific embodiments, R2 is selected from halogen, such as F, Cl, Br, I, preferably F.

[0021] In certain specific embodiments, X1 and X2 are both selected from CH2.

[0022] In certain specific embodiments, X3 and X4 are both selected from CH2.

[0023] In certain specific embodiments, X1, X2, X3, and X4 are all selected from CH2.

[0024] In certain specific embodiments, R1 is selected from C1-C3 alkyl, C3-C6 cycloalkyl, 3-6 membered alicyclic group containing 1-2 atoms selected from N, O, S, 5-10 membered aryl, 5-10 membered heteroaryl, -NR3R4, 7-10 membered spirocyclic group containing 0-3 heteroatoms selected from N, O, S; wherein R3 is selected from H, C1-C3 alkyl; R4 is selected from C1-C3 alkyl or C1-C3 haloalkyl;

[0025] In certain specific embodiments, R1 is optionally replaced by one or more selected from halogen, C1-C3 alkyl, C1-C3 alkoxy, cyano, -NHCO-(C1-C3 alkyl), -COR x wherein Rx is C1-C6 alkyl, C2-C4 alkenyl or -CH=CHCH2N(CH3)2. In certain specific embodiments, R1 is selected from 5-10 membered aryl, 5-10 membered heteroaryl, -NR3R4.

[0026] In certain specific embodiments, R1 is selected from 5-10 membered aryl or 5-10 membered heteroaryl, wherein the 5-10 membered aryl or 5-10 membered heteroaryl is selected from 5-10 membered monocyclic aryl, 5-10 membered bicyclic aryl, 5-10 membered monoheterocyclic aryl or 5-10 membered bicyclic heterocyclic aryl.

[0027] In certain specific embodiments, R1 is selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, morpholinyl, tetrahydropyranyl, pyrazolyl, thiazolyl, thienyl, pyrrolyl, imidazolyl, phenyl, pyridinyl, 2(1H)pyridonyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolinyl, -NHCH2CF3, -NHCH3, -N(CH3)2, -NCH3(CH2CH3), or

[0028] In certain specific embodiments, R1 is selected from methyl, ethyl, oxetanyl, azetidinyl, morpholinyl, pyrazolyl, thiazolyl, phenyl, pyridinyl, pyridonyl, quinolinyl, -NHCH2CF3, -NHCH3, -NHCH2CH3, -N(CH3)2, -NCH3(CH2CH3).

[0029] In some specific embodiments, ------ represents a chemical bond. In some specific embodiments, R1 is optionally substituted by one or more groups selected from fluorine, chlorine, bromine, iodine, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -NHCOCH3, -CH=CHCH2N(CH3)2.

[0030] In certain specific embodiments, the present application provides a compound shown in the following structure, a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof:

[0031]

[0032]

[0033]

[0034]

[0035] The second object of the present application is to provide a pharmaceutical composition comprising a therapeutically effective dose of a compound of formula (I) or (II), a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof.

[0036] The third object of the present application is to provide a pharmaceutical composition comprising a therapeutically effective dose of a compound of formula (I) or (II), a pharmaceutically acceptable salt, hydrate, isomer, prodrug or a mixture thereof, and a pharmaceutically acceptable excipient or carrier.

[0037] The fourth object of the present application is to provide the aforementioned compound, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, for use in the preparation of a drug for preventing and treating diseases related to the interaction with Menin-MLL protein. The diseases related to the interaction with Menin-MLL protein include leukemia, leukemia-related complications, lymphoma, solid tumors or diabetes. The leukemia includes acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia or myelodysplastic syndrome, etc. The acute myeloid leukemia includes mixed rearrangement leukemia or nucleoside phosphorylase 1 (NPM1) mutation leukemia, etc. The leukemia-related complications include leukemic meningitis, etc. The solid tumors include pancreatic cancer, colon cancer, liver cancer, glioblastoma, lung cancer, breast cancer, prostate cancer, etc. The lymphomas include Hodgkin's lymphoma, non-Hodgkin's lymphoma, plasma cell tumor, multiple myeloma, cutaneous T-cell lymphoma, lymphoid tumor, etc. DETAILED DESCRIPTION

[0038] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0039] Definitions and general notes:

[0040] "Substitution" means that a hydrogen atom in a molecule is replaced by another different atom or group.

[0041] "------" indicates a possible chemical bond, which may or may not exist. For example When “------” exists, it is a double bond; when “------” does not exist, it is a single bond.

[0042] Indicates the connection position of the group with other structures, such as The wavy line indicates that the sulfonamide group is connected to other groups through the N atom position.

[0043] "Alkyl" refers to a saturated hydrocarbon group consisting only of carbon atoms and hydrogen atoms, with single bonds between carbons and between carbons and hydrogens, and the alkyl group can be straight or branched. Representative branched alkyl groups have one, two or three branches. The alkyl group may be optionally substituted with one or more substituents as defined herein. Alkyl includes, but is not limited to, methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl) and hexyl. Alkyl can also be part of other groups, which can be alkoxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, etc.

[0044] "Haloalkyl" means that the hydrogen atoms in the alkyl group may be optionally substituted by one or more halogen atoms, and the halogen may be F, Cl, Br, I; haloalkyl includes but is not limited to CF3, (CH2)F, CHF2, CH2Br, CH2CF3 and CH2CH2F.

[0045] "Cycloalkyl" refers to a saturated or non-aromatic partially saturated ring having a single ring or multiple rings (fused, bridged, spiro). For example, examples of monocyclic alkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.

[0046] "Aliphatic heterocyclic group" refers to a saturated ring or a non-aromatic partially saturated ring having a single ring or multiple rings (fused, bridged, spiro) containing at least one or more heteroatoms; wherein the heteroatom refers to N, O and S, etc. It usually refers to a monovalent saturated or partially unsaturated monocyclic or polycyclic ring system with multiple ring atoms, which contains 1, 2 or 3 ring heteroatoms selected from N, O and S, and the remaining ring atoms are carbon. Including but not limited to, for example, oxacyclopropyl, morpholinyl, aziridine, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, etc.

[0047] "Aryl" refers to an aromatic hydrocarbon group having multiple carbon atoms. Aryl is typically a monocyclic, bicyclic or tricyclic aromatic group having multiple carbon atoms, etc. In addition, the term "aryl" as used herein refers to an aromatic substituent that can be a single aromatic ring or multiple aromatic rings fused together.

[0048] "Heteroaryl" is an aromatic unsaturated ring containing at least one heteroatom; wherein the heteroatom refers to N, O and S, etc. It is usually an aromatic monocyclic, bicyclic hydrocarbon or cyclic ring containing multiple ring atoms, wherein one or more ring atoms are selected from O, N, S. Heteroaryl represents, for example, pyridyl, indolyl, quinoxalinyl, quinolyl, isoquinolyl, benzothienyl, benzofuranyl, benzothienyl, benzopyranyl, benzothiapyranyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, oxadiazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, etc.

[0049] "Parallel ring" or "parallel heterocyclic ring" refers to rings connected by a common ring edge.

[0050] The term "member" refers to the number of skeleton atoms constituting the ring. Typical 5-membered rings include, for example, cyclopentyl, pyrrole, imidazole, thiazole, furan, and thiophene; typical 6-membered rings include, for example, cyclohexyl, pyridine, pyran, pyrazine, thiopyran, pyridazine, pyrimidine, benzene, etc. Among them, a ring containing heteroatoms in the skeleton atoms is a heterocycle; an aromatic group containing heteroatoms is a heteroaryl group; and a non-aromatic group containing heteroatoms is a heterocycloalkyl group.

[0051] "Heteroatom" refers to an atom other than carbon or hydrogen. One or more heteroatoms in the heterocycle of the present application can be independently selected from O, S, and N, but are not limited thereto.

[0052] "Optionally" means that the subsequently described event or circumstance can be freely chosen or not chosen.

[0053] "Spirocyclyl" refers to an aliphatic heteroalkyl group containing a spirocyclic structure, non-limiting examples of which include:

[0054]

[0055] "Halogen" refers to fluorine, chlorine, bromine or iodine.

[0056] "Alkoxy" refers to an -O-alkyl group.

[0057] "Cyano" refers to -CN.

[0058] "Hydrate" refers to an aggregate of the compounds of the present invention containing one or more water molecules, including hemihydrate, monohydrate, dihydrate, trihydrate, etc.

[0059] "Isomer" means that when the compounds of the present invention contain one or more asymmetric centers, they can exist as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and single diastereomers. The compounds of the present invention may have asymmetric centers, which result in the existence of two optical isomers. The scope of the present invention includes all possible optical isomers and their mixtures. If the compounds of the present invention contain olefin double bonds, unless otherwise specified, the scope of the present invention includes cis isomers and trans isomers. The compounds of the present invention can exist in the form of tautomers (a kind of functional group isomers), which have different hydrogen attachment points through one or more double bond displacements, for example, a ketone and its enol form are keto-enol tautomers. Each tautomer and its mixture are within the scope of the present invention. Enantiomers of all compounds. Diastereomers, racemates, mesomorphs, cis-trans isomers, tautomers, geometric isomers, epimers and mixtures thereof are all within the scope of the present invention.

[0060] "Prodrug" refers to a derivative compound that can directly or indirectly provide the compound of the present invention after being applied to an individual. Particularly preferred derivative compounds or prodrugs are compounds that can improve the bioavailability of the compound of the present invention when applied to an individual (e.g., more easily absorbed into the blood), or compounds that promote the delivery of the parent compound to the site of action (e.g., lymphatic system). Unless otherwise indicated, all prodrug forms of the compounds of the present invention are within the scope of the present invention, and various prodrug forms are known in the art, for example, see T.Higuchi, V.Stella, Pro-drugs as Novel Drug Delivery Systems [J], American Chemical Society, Vol.14, 1975. In addition, the present invention also encompasses compounds of the present invention containing protecting groups. In any process of preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive groups or reactive groups on any related molecules, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved by conventional protecting groups, such as the protecting groups described in TWGreene, PGM Wuts, Protective Groups in Organic Synthesis [M], John Wiley & Sons, 2006. These protecting groups may be removed at an appropriate subsequent stage using methods known in the art.

[0061] "Cm-Cn" means that the part modified by the term has mn carbon atoms (n is greater than m, and both are integers). For example, C1-C6 means that the part modified by the term has 1-6 carbon atoms, such as 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms. C1-C3 means that the part modified by the term has 1-3 carbon atoms, such as 1 carbon atom, 2 carbon atoms, 3 carbon atoms.

[0062] "Pharmaceutical composition" refers to a preparation of a compound of the present invention and a medium generally accepted in the art for delivering biologically active compounds to mammals (e.g., humans). The medium includes a pharmaceutically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0063] "Pharmaceutically acceptable" refers to substances such as carriers, diluents or excipients that do not affect the biological activity or properties of the compounds of the invention, and are relatively non-toxic, i.e., the substance can be administered to an individual without causing adverse biological reactions or interacting with any component contained in the composition in an adverse manner. For example, "excipients" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the relevant government regulatory authorities as acceptable for use by humans or livestock.

[0064] "Pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts, and the like.

[0065] Abbreviation

[0066] PhLi stands for phenyllithium

[0067] s-BuLi means sec-butyllithium

[0068] TMEDA stands for N,N,N',N'-tetramethylethylenediamine

[0069] CbzCl represents benzyl chloroformate

[0070] MsCl stands for methanesulfonyl chloride

[0071] TEA stands for triethylamine

[0072] DMAP stands for 4-dimethylaminopyridine

[0073] DCM means dichloromethane

[0074] THF stands for tetrahydrofuran

[0075] ACN stands for acetonitrile

[0076] DMF stands for N,N-dimethylformamide

[0077] AcOH stands for glacial acetic acid

[0078] TsOH represents p-toluenesulfonic acid

[0079] MeOH stands for methanol

[0080] EtOH stands for ethanol

[0081] mCPBA stands for 3-chloroperbenzoic acid

[0082] HATU stands for O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate

[0083] DIEA stands for ethyl diisopropylamine

[0084] i-PrOH represents isopropanol

[0085] LHA stands for lithium aluminum hydride

[0086] DMP stands for Dess-Martin reagent

[0087] NH4OAc represents ammonium acetate

[0088] NCS stands for N-chlorosuccinimide

[0089] Ms2O represents methanesulfonic anhydride

[0090] IPA stands for isopropyl alcohol

[0091] AcONa stands for sodium acetate

[0092] DBU stands for 1,8-diazabicyclo[5.4.0]undec-7-ene

[0093] Pd(dppf)Cl2 stands for [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride

[0094] Pd2(dba)3 stands for tris(dibenzylideneacetone)dipalladium

[0095] XantPhos stands for 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[0096] PCC stands for pyridinium chlorochromate

[0097] NaBH(OAc)3 represents sodium triacetoxyborohydride

[0098] Preparation of intermediates

[0099] Preparation Example 1: Preparation of benzyl 1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate

[0100] Step 1: Preparation of tert-butyl 3-(1-azabicyclo[1.1.0]butan-3-yl)-3-hydroxyazetidine-1-carboxylate

[0101]

[0102] Dissolve 2,3-dibromopropane-1-amine hydrobromide (4.8 g, 16.12 mmol) in anhydrous tetrahydrofuran (60 mL) and cool the reaction system to -65°C. Then slowly drop a solution of phenyl lithium (2N, 48.35 mmol) in n-butyl ether and keep the temperature no higher than -60°C. After the addition is complete, stir the reaction system at -65°C for 2 hours. Then remove the low temperature bath, quickly warm to room temperature and stir at room temperature for 10 minutes. Cool the reaction system to -65°C again, and drop a mixed solution of N,N,N',N'-tetramethylethylenediamine (2.25 g, 19.34 mmol) and sec-butyllithium (1.3N, 19.34 mmol) in cyclohexane and n-hexane in sequence and keep the temperature no higher than -60°C. After the addition was completed, the reaction was stirred at -65 ° C for 1 hour, and then a tetrahydrofuran solution of tert-butyl 3-oxoazetidine-1-carboxylate (3.59 g, 20.95 mmol) was slowly added dropwise; after the addition was completed, the reaction system was stirred at -65 ° C for 1 hour. LCMS detection showed that the raw material reaction was complete. Water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phases were combined, dried and concentrated, and directly used in the next step reaction.

[0103] Step 2: Preparation of 1-benzyl 1'-(tert-butyl) 3'-hydroxy-3-iodo-[3,3'-diazetidine]-1,1'-dicarboxylic acid

[0104]

[0105] Dissolve tert-butyl 3-(1-azabicyclo[1.1.0]butan-3-yl)-3-hydroxyazetidine-1-carboxylate (2.41 g, 10.65 mmol) and sodium iodide (3.19 g, 21.30 mmol) in acetonitrile (30 mL), cool the reaction system to 0°C, and then slowly add benzyl chloroformate (2.18 g, 12.78 mmol). After the addition is complete, stir the reaction at 0°C for 30 minutes. After the reaction is complete, 4.58 g of the title compound is obtained by column chromatography.

[0106] MS (ESI) m / z (M+H-100) + =389.1

[0107] Step 3: Preparation of 1-benzyl 1'-(tert-butyl) 3-iodo-3'-((methylsulfonyl)oxy)-[3,3'-diazetidine]-1,1'-dicarboxylic acid

[0108]

[0109] Dissolve 1-benzyl 1'-(tert-butyl) 3'-hydroxy-3-iodo-[3,3'-diazetidine]-1,1'-dicarboxylic acid (2.12 g, 4.34 mmol) in dichloromethane (50 mL). After cooling the reaction system to 0°C, add triethylamine (878 mg, 8.68 mmol) and 4-dimethylaminopyridine (1.06 g, 8.68 mmol); then slowly add methylsulfonyl chloride (995 mg, 8.68 mmol) dropwise. After the addition is complete, stir the reaction system at 0°C for 30 minutes. After the reaction is complete, 1.82 g of the title compound is obtained by column chromatography.

[0110] MS (ESI) m / z (M+H-100) + =467.1.

[0111] Step 4: Preparation of 1-benzyl 1'-(tert-butyl) 2H,2'H-[3,3'-diazetidinylidene]-1,1'(4H,4'H)-dicarboxylic acid

[0112]

[0113] 1-Benzyl 1'-(tert-butyl) 3-iodo-3'-((methylsulfonyl)oxy)-[3,3'-diazetidine]-1,1'-dicarboxylic acid (1.8 g, 3.18 mmol) was dissolved in acetic acid (20 mL). Zinc powder (1.04 g, 15.89 mmol) was then added. After the addition was completed, the reaction system was stirred at room temperature for 2 hours. After the reaction was complete, 980 mg of the title compound was obtained by purification.

[0114] MS (ESI) m / z (M+H-100) + =245.2.

[0115] 1 H NMR (400MHz, Chloroform-d) δ7.35 (d, J = 3.8Hz, 5H), 5.11 (s, 2H), 4.49 (m, 4H), 4.43–4.38 (m, 4H), 1.44 (s, 9H).

[0116] Step 5: Preparation of benzyl 1',4'-dihydro-2H,2'H-[3,3'-diazetidinylidene]-1(4H)-carboxylate

[0117]

[0118] 1-Benzyl 1'-(tert-butyl) 2H,2'H-[3,3'-diazetidinylidene]-1,1'(4H,4'H)-dicarboxylate (980 mg, 2.80 mmol) was dissolved in ethanol (32 mL), and then p-toluenesulfonic acid (1.6 g, 9.29 mmol) was added, and the reaction system was stirred at 50°C for 6 hours. After the reaction was complete, 1.16 g of the title compound p-toluenesulfonate was obtained by column chromatography purification.

[0119] MS (ESI) m / z (M+H) + =245.1.

[0120] Preparation Example 2: Preparation of 3-(pyrrolidino-3-ylidene)azetidine-1-carboxylic acid benzyl ester

[0121]

[0122] Step 1: Preparation of tert-butyl 3-(1-azabicyclo[1.1.0]butan-3-yl)-3-hydroxypyrrolidine-1-carboxylate

[0123]

[0124] 2,3-Dibromopropane-1-amine hydrobromide (20 g, 67.84 mmol) was dissolved in tetrahydrofuran, the reaction system was cooled to -65°C, and then a solution of phenyllithium (1N, 203.52 mmol) in n-butyl ether was slowly added dropwise while maintaining the temperature not higher than -60°C. After the addition was completed, the reaction was stirred at -65°C for 2 hours, the low temperature bath was removed and the temperature was quickly raised to room temperature, and stirred at room temperature for 10 minutes; the temperature of the reaction system was cooled to -65°C again, and a mixed solution of N,N,N',N'-tetramethylethylenediamine (9.46 g, 81.41 mmol) and sec-butyllithium (1.3N, 81.41 mmol) in cyclohexane and n-hexane was added dropwise in sequence and the temperature was kept not higher than -60°C. After the addition was completed, the reaction system was stirred at -65°C for 1 hour; then a tetrahydrofuran solution of tert-butyl 3-oxopyrrolidine-1-carboxylate (16.33 g, 88.19 mmol) was slowly added dropwise. After the addition was completed, the reaction was stirred at -65°C for 1 hour. LCMS showed that the raw material reaction was complete, water was added to quench the reaction solution, extracted with ethyl acetate, the organic phases were combined, and concentrated under reduced pressure to obtain 25 g of a light yellow jelly, which was directly used in the next step.

[0125] MS (ESI) m / z (M+H) + =241.3.

[0126] Step 2: Preparation of tert-butyl 3-(1-[(benzyloxy)carbonyl]-3-iodoazetidin-3-yl)-3-hydroxypyrrolidine-1-carboxylate

[0127]

[0128] 3-(1-azabicyclo[1.1.0]butan-3-yl)-3-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester (15g, 62.42mmol) was dissolved in acetonitrile solution, followed by the addition of sodium iodide (18.71g, 124.84mmol), the reaction system was cooled to 0°C, and then benzyl chloroformate (12.78g, 74.90mmol) was slowly added. After the addition was completed, the reaction system was stirred at 0°C for 30 minutes. LCMS showed that the raw material was completely reacted, and the reaction system was quenched with sodium bisulfite, and ethyl acetate was added for extraction, the organic phases were combined, and the organic phases were concentrated under reduced pressure to obtain a crude product, which was separated by column chromatography to obtain 15g of the title compound as a yellow gum.

[0129] MS (ESI) m / z (M+H-100) + =403.3.

[0130] Step 3: Preparation of tert-butyl 3-(1-[(benzyloxy)carbonyl]azetidin-3-ylidene)pyrrolidine-1-carboxylate

[0131]

[0132] 3-(1-[(Benzyloxy)carbonyl]-3-iodoazetidin-3-yl)-3-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester (12 g, 23.89 mmol) was dissolved in dichloromethane, followed by the addition of 4-dimethylaminopyridine (5.84 g, 47.78 mmol), triethylamine (4.83 g, 47.78 mmol) and methanesulfonyl chloride (5.47 g, 47.78 mmol). After the addition was completed, the reaction system was stirred at room temperature for 36 hours. LCMS showed that the raw material was not completely reacted. The reaction solution was concentrated under reduced pressure, diluted with water, extracted with dichloromethane, and the organic phases were combined and concentrated under reduced pressure to obtain a crude product. The crude product was separated by column chromatography to obtain 4 g of the title compound as a yellow gum.

[0133] MS (ESI) m / z (M+H-100) + =259.2.

[0134] Step 4: Preparation of benzyl 3-(pyrrolidin-3-ylidene)azetidine-1-carboxylate

[0135]

[0136] Tert-butyl 3-(1-[(Benzyloxy)carbonyl]azetidin-3-ylidene)pyrrolidine-1-carboxylate (0.42 g, 1.17 mmol) was dissolved in dichloromethane, and then a dioxane hydrochloride solution was added. After the addition was completed, the reaction system was stirred at room temperature for 1 hour. LCMS showed that the raw materials were completely reacted. The reaction solution was concentrated under reduced pressure to obtain 0.4 g of a yellowish jelly. The title compound was directly used in the next step reaction.

[0137] MS (ESI) m / z (M+H) + =259.2.

[0138] Preparation Example 3: Preparation of 3-(piperidin-4-ylidene)azetidine-1-carboxylic acid benzyl ester

[0139]

[0140] The title compound was prepared by using the corresponding commercial reagents and the product in the above Preparation Example as raw materials and using a preparation method similar to the above Preparation Example 2.

[0141] MS (ESI) m / z (M+H) + =273.2.

[0142] Preparation Example 4: Preparation of 2-((4-chloropyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0143]

[0144] Step 1: Preparation of N-ethyl-5-fluoro-2-hydroxy-N-(propan-2-yl)benzamide

[0145]

[0146] At room temperature, 5-fluoro-2-hydroxybenzoic acid (100 g, 640.57 mmol), oxalyl chloride (203 g, 1601.43 mmol) and dichloromethane (600 mL) were added to a 1L reaction bottle, stirred, and N,N-dimethylformamide (140 mg, 1.92 mmol) was slowly added dropwise, and a large number of bubbles were generated. The reaction system was then heated to reflux and reacted overnight. After the reaction was completed, the solvent and excess oxalyl chloride were removed by rotary evaporation. Dichloromethane (600 mL) was added to the reaction bottle to dissolve the residue, and triethylamine (191 g, 1890.48 mmol) was slowly added under ice bath conditions, and finally ethyl (propan-2-yl) amine (82 g, 945.24 mmol) was slowly added. After the reaction was completed, the solvent was removed by rotary evaporation to obtain a crude product. The obtained crude product was separated by column chromatography to finally obtain 120 g of N-ethyl-5-fluoro-2-hydroxy-N-(propan-2-yl) benzamide.

[0147] MS (ESI) m / z (M+H) + =226.2.

[0148] Step 2: Preparation of N-ethyl-5-fluoro-N-(propan-2-yl)-2-(pyrimidin-5-yloxy)benzamide

[0149]

[0150] At room temperature, N-ethyl-5-fluoro-2-hydroxy-N-(propan-2-yl)benzamide (25 g, 110.98 mmol), 5-bromopyrimidine (23 g, 144.27 mmol), cesium carbonate (108 g, 332.94 mmol) and N,N-dimethylformamide (250 mL) were added to a 500 mL single-mouth reaction bottle. After stirring evenly, the temperature was slowly raised to 135°C and the reaction was allowed to proceed overnight. After the reaction was completed, water was added, extracted with ethyl acetate, the organic phases were combined, and the organic phases were concentrated under reduced pressure to obtain a crude product. The crude product was separated by column chromatography to obtain 30 g of the product N-ethyl-5-fluoro-N-(propan-2-yl)-2-(pyrimidin-5-yloxy)benzamide.

[0151] MS (ESI) m / z (M+H) + =304.2.

[0152] Step 3: Preparation of 5-(2-(ethyl(propan-2-yl)carbamoyl)-4-fluorophenoxy)pyrimidin-1-ium-1-acid ester

[0153]

[0154] In an ice bath, 3-chloroperoxybenzoic acid (17 g, 98.90 mmol) was slowly added to a mixture of N-ethyl-5-fluoro-N-(propan-2-yl)-2-(pyrimidin-5-yloxy)benzamide (30 g, 98.90 mmol) and dichloromethane (300 mL). After the addition, the mixture was naturally warmed to room temperature under nitrogen protection and reacted overnight. After the reaction was completed, saturated sodium bisulfite solution was added to quench the reaction, and the solvent was removed by rotary evaporation to obtain 30 g of 5-(2-(ethyl(propan-2-yl)carbamoyl)-4-fluorophenoxy)pyrimidin-1-ium-1-acid ester. The crude product was directly used in the next step without purification.

[0155] MS (ESI) m / z (M+H) + =320.2.

[0156] Step 4: Preparation of 2-((4-chloropyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0157] Under ice bath conditions, 5-(2-bromo-4-fluorophenoxy)pyrimidin-1-ium-1-acid ester (39g, 122.13mmol) was dissolved in chloroform (400mL), and then triethylamine (31g, 305.32mmol) was added; after stirring evenly, phosphorus oxychloride (2.58g, 168.55mmol) was slowly added, and stirring was continued for 5 minutes under ice bath, and then the temperature was slowly raised to 65°C for 2 hours. Monitor the reaction to be complete, directly remove the solvent by rotary evaporation, add 100mL of sodium bicarbonate aqueous solution to the system to quench the reaction, extract three times with ethyl acetate, combine the organic phases, backwash once with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. Purify by column chromatography to obtain 15g of 2-((4-chloropyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide.

[0158] MS (ESI) m / z (M+H) + =338.2.

[0159] Preparation Example 5: 2-((4-(1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0160]

[0161] Step 1: Preparation of benzyl 3-(1-(5-(2-(ethyl(propan-2-yl)carbamoyl)phenoxy)pyrimidin-4-yl)azetidin-3-ylidene)azetidine-1-carboxylate

[0162]

[0163] At room temperature, 2-[(4-chloropyrimidin-5-yl)oxy]-N-ethyl-N-(propan-2-yl)benzamide (2.5 g, 7.82 mmol), isopropanol (80 mL) and 3-(azetidin-3-ylidene)azetidin-1-carboxylic acid benzyl ester p-toluenesulfonate (3.91 g, 9.38 mmol) were added to the reaction bottle; stirred evenly, triethylamine (2.37 g, 23.46 mmol) was slowly added, and the temperature was gradually raised to 85°C. After reacting for 2 hours, LCMS monitored that the reaction was complete, water was added, ethyl acetate was extracted, the organic phases were combined, and the organic phases were concentrated under reduced pressure to obtain a crude product. The obtained crude product was separated by column chromatography to obtain 3.72 g of 3-(1-(5-(2-(ethyl(propan-2-yl)carbamoyl)phenoxy)pyrimidin-4-yl)azetidin-3-ylidene)azetidin-1-carboxylic acid benzyl ester.

[0164] MS (ESI) m / z (M+H) + =546.2.

[0165] Step 2: Preparation of 2-((4-(1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0166]

[0167] At room temperature, trifluoroacetic acid (20 mL) was added to the raw material 3-(1-(5-(2-(propan-2-yl)carbamoylethyl)-4-fluorophenoxy)pyrimidin-4-yl)azetidine-3-ylidene)azetidine-1-carboxylic acid benzyl ester (3.7 g, 6.78 mmol), and the temperature was slowly raised to 65° C. for 1 hour. LCMS monitored that the raw material reaction was complete, and the trifluoroacetic acid was removed by concentration under reduced pressure. The obtained crude product was dissolved in a mixed solution of methanol and dichloromethane, and sodium bicarbonate was added and stirred for 0.5 hours. Sodium bicarbonate was removed by filtration, and the organic phase was concentrated under reduced pressure to obtain a crude product. The obtained crude product was separated by column chromatography to obtain 2.79 g of 2-((4-(1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide.

[0168] MS (ESI) m / z (M+H) + =412.2.

[0169] Preparation Example 6: tert-Butyl trans-(4-formylcyclohexyl)carbamate

[0170]

[0171] Step 1: Preparation of trans-tert-butyl N-[(4-(hydroxymethyl)cyclohexyl]carbamate

[0172]

[0173] Trans-4-{[(tert-butoxy)carbonyl]amino}cyclohexane-1-carboxylic acid methyl ester (25.0g, 97.15mmol) was dissolved in dry tetrahydrofuran (350.0mL), replaced with nitrogen three times, cooled in an ice-water bath, and slowly added lithium aluminum hydride (4.42g, 116.58mmol). After the addition was completed, reacted at room temperature for 2 hours. TLC monitoring showed that the raw material reacted completely, cooled in an ice-water bath, and slowly added water to quench the reaction. Add 15% NaOH aqueous solution and stir at room temperature for 1 hour. Filter through diatomaceous earth and wash with tetrahydrofuran. After concentrating the filtrate, 18.0g of trans-N-[(4-(hydroxymethyl)cyclohexyl]carbamic acid tert-butyl ester was obtained, which was directly used in the next step reaction.

[0174] MS (ESI) m / z (M+H) + =230.2.

[0175] Step 2: Preparation of tert-butyl trans-(4-formylcyclohexyl)carbamate

[0176]

[0177] Add trans-N-[(4-(hydroxymethyl)cyclohexyl]carbamic acid tert-butyl ester (17.0 g, 74.45 mmol), sodium bicarbonate (12.51 g, 148.9 mmol) and dichloromethane (500.0 mL) to the reaction bottle. After stirring evenly, slowly add Dess-Martin reagent (37.89 g, 89.34 mmol) to the reaction system. React at room temperature for 1 hour, and TLC monitoring shows that the raw material reacts completely. Add saturated sodium bicarbonate aqueous solution to quench the reaction, extract three times with dichloromethane (200.0 mL), dry with anhydrous sodium sulfate, filter under reduced pressure, and concentrate the organic phase. The concentrate is purified by silica gel column to obtain 11.3 g of trans-(4-formylcyclohexyl)carbamic acid tert-butyl ester.

[0178] MS (ESI) m / z (M+H) + =228.2.

[0179] Preparation Example 7: 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0180]

[0181] Step 1: Preparation of tert-butyl (trans-4-((1'-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)methyl)cyclohexyl)carbamate

[0182]

[0183] At room temperature, tert-butyl trans-(4-formylcyclohexyl)carbamate (2.16 g, 9.52 mmol) and sodium cyanoborohydride (598 mg, 9.52 mmol) were added to a methanol solution of 2-((4-(1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (0.98 g, 2.38 mmol). After the addition was completed, the system was reacted at room temperature for 2 hours. LCMS confirmed that the reaction was complete. Water was added to quench the reaction, and the mixture was concentrated under reduced pressure. The crude product was purified by column chromatography to obtain 1.06 g of a white solid.)

[0184] MS (ESI) m / z (M+H) + =623.2.

[0185] Step 2: Preparation of 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0186]

[0187] In an ice-water bath, trifluoroacetic acid (4.59 g, 40.26 mmol) was added to a dichloromethane solution of tert-butyl (trans-4-((1'-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)methyl)cyclohexyl)carbamate (1.06 g, 1.70 mmol), and the mixture was heated naturally to react overnight. LCMS confirmed that the reaction was complete, and the mixture was concentrated under reduced pressure to obtain 1.08 g of the title compound as a colorless oil, which was used directly in the next step without purification.

[0188] MS (ESI) m / z (M+H) + =523.2.

[0189] Example 1: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-((trans-4-(methylsulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0190]

[0191] 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (100 mg, 0.19 mmol) was dissolved in dichloromethane (15 mL), and triethylamine (76.90 mg, 0.76 mmol) and methanesulfonyl chloride (32.65 mg, 0.29 mmol) were added in sequence. After the addition, the reaction system was reacted at 25°C for 0.5 hours. After LCMS showed that the reaction was complete, water was added to the system, and dichloromethane was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by Pre-HPLC to obtain 9.03 mg of the title compound as a white solid.

[0192] MS (ESI) m / z (M+H) + =601.1.

[0193] 1H NMR(400MHz,DMSO-d6)δ8.32(s,1H),7.78(s,1H),7.31–7.22(m,2H),7.08–7.02(m,1H),6.99–6.94(m,1H),4.67–4.34(m,4H),3.77–3.65(m,5H ),3.26–3.12(m,1H),3.01–2.98(m,1H),2.88(s,3H),2.28(d,J=6.5Hz, 2H),1.87(d,J=12.3Hz,2H),1.71(d,J=12.9Hz,2H),1.31–0.74(m,15H).

[0194] Example 2: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-(methylsulfonamido)cyclohexyl)-1',4'-dihydro-2H,2'H-[3,3'-diazacyclyl]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0195]

[0196] Step 1: Preparation of tert-butyl-(trans-4-(1'-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)cyclohexyl)carbamate

[0197]

[0198] At room temperature, 2-((4-(1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (250 mg, 0.61 mmol), tert-butyl N-(4-oxocyclohexyl)carbamate (169.12 mg, 0.79 mmol) and methanol (10 mL) were added sequentially into a single-necked bottle. After stirring evenly, sodium cyanoborohydride (57.50 mg, 0.92 mmol) was added, and stirring was continued. The reaction was completed after 1 hour. A small amount of saturated ammonium chloride solution was added to quench the reaction, and the mixture was filtered through diatomaceous earth. The filtrate was collected and the solvent was removed by rotary evaporation to obtain tert-butyl-(trans-4-(1'-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)cyclohexyl)carbamate 360 ​​mg. The crude product was directly used in the next step without purification.

[0199] MS (ESI) m / z (M+H) + =609.2.

[0200] Step 2: Preparation of 2-((4-(1'-(trans-4-aminocyclohexyl)-1',4'-dihydro-2H,2'H-[3,3'-diazacyclyl]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0201]

[0202] At room temperature, tert-butyl-(trans-4-(1'-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)cyclohexyl)carbamate (274 mg, 0.45 mmol) was added to the reaction bottle; after adding dichloromethane (10 mL) to dissolve, trifluoroacetic acid (256.55 mg, 2.25 mmol) was slowly added and stirred at room temperature for 5 hours. After the reaction was completed, the solvent was removed by rotary evaporation to obtain 217.5 mg of crude 2-((4-(1'-(trans-4-aminocyclohexyl)-1',4'-dihydro-2H,2'H-[3,3'-diazacyclyl]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide, which was used directly in the next reaction without purification.

[0203] MS (ESI) m / z (M+H) + =509.2.

[0204] Step 3: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-(methylsulfonamido)cyclohexyl)-1',4'-dihydro-2H,2'H-[3,3'-diazacyclyl]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0205]

[0206] 2-((4-(1'-(trans-4-aminocyclohexyl)-1',4'-dihydro-2H,2'H-[3,3'-diazacyclyl]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (66 mg, 0.13 mmol) was added to the reaction bottle, and dichloromethane (10 mL) and triethylamine (530 mg, 0.52 mmol) were added to dissolve, and the reaction system was transferred to an ice-water bath. Methanesulfonyl chloride (300 mg, 0.26 mmol) was slowly added dropwise, and solids were produced during the addition. After 0.5 hours of reaction, LCMS monitored the reaction to be complete. The reaction solution was added dropwise to a saturated sodium bicarbonate solution, separated, and the organic phase was collected. The aqueous phase was extracted once with dichloromethane, the organic phases were combined, and the solvent was removed. The resulting crude product was purified by Pre-HPLC to obtain 6 mg of the title compound.

[0207] MS (ESI) m / z (M+H) + =587.2.

[0208] 1H NMR (400MHz, Chloroform-d) δ8.42 (s, 1H), 7.83 (s, 1H), 7.00 (d, J = 7.5Hz, 2H), 6. 77–6.67(m,1H),4.86–4.57(m,4H),4.11(d,J=7.2Hz,1H),3.97–3.78(m,4H),3.53 –3.42(m,1H),3.38–3.24(m,2H),3.19(d,J=7.3Hz,1H),2.98(s,3H),2.18–2.04(m ,2H),1.89–1.78(m,2H),1.67–1.51(m,2H),1.32–1.20(m,7H),1.20–1.06(m,5H).

[0209] Example 3: Preparation of N-ethyl-2-((4-(1'-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0210]

[0211] 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (100 mg, 0.19 mmol) was dissolved in dichloromethane (15 mL), followed by the addition of triethylamine (76.90 mg, 0.76 mmol) and ethanesulfonyl chloride (36.65 mg, 0.29 mmol). The reaction system was reacted at 25°C for 0.5 hours. After LCMS showed that the reaction was complete, 10 mL of water was added to the system, and the dichloromethane was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by Pre-HPLC to obtain 23.15 mg of a white solid.

[0212] MS (ESI) m / z (M+H) + =615.2.

[0213] 1 H NMR(400MHz, DMSO-d6)δ8.32(s,1H),7.78(s,1H),7.31–7.22(m,2H),7.09–6.97(m,2H),4.67–4.55(m,4H),3.77–3.64(m,5H), 3.24–3.11(m,1H),2.95(q,J=7.3Hz,3H),2.27(d,J=6.6Hz,2H),1.92–1.78(m,2H),1.70(d,J=12.8Hz,2H),1.34–0.70(m,18H).

[0214] Example 4: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-(oxetane-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0215]

[0216] Step 1: Preparation of 3-(benzylthio)oxetane

[0217]

[0218] 3-Iodooxetane (3 g, 16.31 mmol) was dissolved in N,N-dimethylformamide (15 mL), followed by the addition of benzyl mercaptan (2.03 g, 16.31 mmol) and potassium carbonate (2.25 g, 16.31 mmol). After the addition, the reaction system was reacted at 60 ° C for 5 hours. After TLC showed that the reaction was complete, 30 mL of water was added to the system, and ethyl acetate was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 2.4 g of a colorless oily liquid crude product, which was directly used in the next step.

[0219] MS (ESI) m / z (M+H) + =181.1.

[0220] Step 2: Preparation of oxetane-3-sulfonyl chloride

[0221]

[0222] 3-(Benzylthio)oxetane (500 mg, 2.77 mmol) was dissolved in acetonitrile (10 mL), followed by the addition of dichlorohydantoin (1091.49 mg, 5.54 mmol), acetic acid (1575 mg, 26.23 mmol) and water (750 mg, 41.62 mmol). After the addition, the reaction system was reacted at 25 ° C for 16 hours. After TLC showed that the reaction was complete, 30 mL of saturated sodium bicarbonate aqueous solution was added to the system, and ethyl acetate was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was slurried with petroleum ether, the filtrate was collected, and concentrated under reduced pressure to obtain 300 mg of a light yellow oily liquid, which was directly used in the next step.

[0223] Step 3: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-(oxetane-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0224]

[0225] 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (160 mg, 0.31 mmol) was dissolved in dichloromethane (15 mL), followed by the addition of triethylamine (125.48 mg, 1.24 mmol) and oxetane-3-sulfonyl chloride (72.81 mg, 0.46 mmol). After the addition, the reaction system was reacted at 25°C for 0.5 hours. After LCMS showed that the reaction was complete, 10 mL of water was added to the system, and the dichloromethane was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by Pre-HPLC to obtain 12.69 mg of a white solid.

[0226] MS (ESI) m / z (M+H) + =643.2.

[0227] 1 H NMR(400MHz, DMSO-d6)δ8.32(s,1H),7.78(s,1H),7.36–7.22(m,3H),7.08–7.01(m,1H),4.77–4.72(m,2H),4.63–4.55(m,6H),4.45–4.31(m,1 H),3.77–3.70(m,1H),3.68–3.62(m,4H),3.27–3.08(m,1H),3.05–2.9 3(m,1H),2.27(d,J=6.6Hz,2H),1.79–1.68(m,4H),1.29–0.77(m,15H).

[0228] Example 5: Preparation of N-ethyl-2-((4-(1'-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-[3,3'-diazetidine]-1-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0229]

[0230] N-ethyl-2-((4-(1'-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide (10 mg, 0.016 mmol) was dissolved in methanol (5 mL). 10% wet palladium carbon (10 mg, 0.094 mmol) was added, the system was replaced with hydrogen three times, and the reaction was carried out at room temperature for 2 hours under an atmosphere of hydrogen of 15 psi. After the reaction was completed, the mixture was filtered with diatomaceous earth and concentrated under reduced pressure. The crude product was purified by Pre-HPLC to obtain 6.27 mg of a white solid.

[0231] MS (ESI) m / z (M+H) + =617.1.

[0232] 1 H NMR(400MHz,DMSO-d6)δ8.29(s,1H),7.77(s,1H),7.33–7.16(m,2H),7.03–6.88(m,2H),4.22–4.12(m,2H),3.95–3.67(m,3 H),3.42–3.19(m,6H),2.73–2.58(m,7H),2.12–2.07(m,2H),1.89–1.75(m,2H),1.67(d,J=13.0Hz,2H),1.33–0.72(m,15H).

[0233] Example 6: N-ethyl-5-fluoro-N-isopropyl-2-((4-(3-(1-(trans-4-(methylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)benzamide

[0234]

[0235] Step 1: Preparation of benzyl 3-(1-((trans-4-((tert-butyloxycarbonyl)amino)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidine-1-carboxylate

[0236]

[0237] Benzyl 3-(pyrrolidine-3-ylidene)azetidine-1-carboxylate (0.32 g, 1.24 mmol) was dissolved in a dichloromethane solution, followed by the addition of N,N-diisopropylethylamine (0.48 g, 3.72 mmol), tert-butyl N-(trans-4-formylcyclohexyl)carbamate (0.34 g, 1.49 mmol) and sodium triacetoxyborohydride (0.53 g, 2.48 mmol). After the addition was completed, the reaction system was stirred at room temperature for 2 hours; LCMS showed that the raw materials reacted completely, the reaction solution was concentrated under reduced pressure, the reaction solution was diluted with water, ethyl acetate was added for extraction, the organic phases were combined, and the organic phases were concentrated under reduced pressure to obtain a crude product, and the obtained crude product was separated by column chromatography to obtain 0.5 g of a brown colloid.

[0238] MS (ESI) m / z (M+H) + =470.2.

[0239] Step 2: Preparation of benzyl 3-(1-((trans-4-aminocyclohexyl)methyl)pyrrolidin-3-ylidene)azetidine-1-carboxylate

[0240]

[0241] Benzyl 3-(1-((trans-4-((tert-butyloxycarbonyl)amino)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidine-1-carboxylate (0.5 g, 1.06 mmol) was dissolved in dichloromethane, and then a dioxane hydrochloride solution was added. After the addition was completed, the reaction system was stirred at room temperature for 1 hour; LCMS showed that the raw materials reacted completely, and the reaction solution was concentrated under reduced pressure to obtain 0.5 g of a yellowish colloid, which was used directly in the next step without purification.

[0242] MS (ESI) m / z (M+H) + =370.2.

[0243] Step 3: Preparation of benzyl 3-(1-((trans-4-(methylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidine-1-carboxylate

[0244]

[0245] Benzyl 3-(1-((trans-4-aminocyclohexyl)methyl)pyrrolidine-3-ylidene)azetidine-1-carboxylate (0.4 g, 1.08 mmol) was dissolved in dichloromethane, followed by the addition of triethylamine (0.66 g, 6.48 mmol), 4-dimethylaminopyridine (0.026 g, 0.22 mmol) and methylsulfonyl chloride (0.37 g, 3.24 mmol); after the addition was completed, the reaction system was stirred at room temperature for 2 hours. LCMS showed that the raw materials were completely reacted. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was dissolved in methanol and purified by prep-HPLC to obtain 42 mg of a yellowish jelly.

[0246] MS (ESI) m / z (M+H) + =448.1.

[0247] Step 4: Preparation of N-(trans-4-((3-(azetidin-3-ylidene)pyrrolidin-1-yl)methyl)cyclohexyl)methanesulfonamide

[0248]

[0249] Benzyl 3-(1-((trans-4-(methylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidine-1-carboxylate (0.04 g, 0.089 mmol) was dissolved in trifluoroacetic acid; after the addition was completed, the reaction system was heated to 60°C and stirred at this temperature for 1 hour. LCMS showed that the raw material was completely reacted, and the reaction solution was concentrated under reduced pressure to obtain 0.04 g of a yellowish solid, which was directly used in the next step.

[0250] MS (ESI) m / z (M+H) + =314.2.

[0251] Step 5: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(3-(1-(trans-4-(methylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)benzamide

[0252]

[0253] N-(trans-4-((3-(azetidin-3-ylidene)pyrrolidin-1-yl)methyl)cyclohexyl)methanesulfonamide (0.04 g, 0.13 mmol) was dissolved in isopropanol; 2-[(4-chloropyrimidin-5-yl)oxy]-N-ethyl-5-fluoro-N-isopropylbenzamide (0.053 g, 0.16 mmol) and triethylamine (0.053 g, 0.52 mmol) were then added. After the addition was completed, the reaction system was heated to 80°C and stirred at this temperature for 4 hours. LCMS showed that the raw material reacted completely, and the reaction solution was concentrated under reduced pressure to obtain a crude product, which was dissolved in methanol and purified by prep-HPLC to obtain 9 mg of an off-white solid.

[0254] MS (ESI) m / z (M+H) + =615.3.

[0255] 1 H NMR(400MHz,Chloroform-d)δ8.41(s,1H),7.82(s,1H),7.07–6.96(m,2H),6 .75–6.71(m,1H),4.78–4.57(m,4H),4.13(d,J=7.6Hz,1H),3.91–3.80(m,1H ),3.59–3.41(m,1H),3.39–3.06(m,4H),2.97(s,3H),2.67–2.36(m,6H),2.0 9(d,J=12.5Hz,2H),1.92(d,J=13.1Hz,2H),1.75(s,2H),1.45–1.03(m,12H).

[0256] Example 7: Preparation of N-ethyl-2-(4-(3-(1-(trans-4-(ethylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0257]

[0258] The title compound was prepared by using the corresponding commercial reagents and the product in the above preparation example as raw materials and using a preparation method similar to that in the above Example 6.

[0259] MS (ESI) m / z (M+H) + =629.1.

[0260] 1H NMR(400MHz,Chloroform-d)δ8.42(s,1H),8.23(s,1H),7.83(d,J=3.4Hz,1H),7.05–6.99(m,2H),6 .75–6.72(m,1H),4.79–4.58(m,4H),4.01(d,J=7.9Hz,1H),3.89–3.80(m,1H),3.52–3.48(m,1H),3. 41–3.09(m,5H),3.05–2.97(m,4H),2.55(d,J=6.9Hz,2H),2.45(s,2H),2.08(d,J=12.5Hz,2H),1.9 3(d,J=13.3Hz,2H),1.62–1.48(m,1H),1.36(t,J=7.4Hz,3H),1.29–1.22(m,6H),1.16–1.07(m,5H).

[0261] Example 8: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(3-(1-((trans-4-(methylsulfonylamino)cyclohexyl)methyl)piperidin-4-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)benzamide

[0262]

[0263] The title compound was prepared by using the corresponding commercial reagents and the product in the above preparation example as raw materials and using a preparation method similar to that in the above Example 6.

[0264] MS (ESI) m / z (M+H) + =629.2.

[0265] 1 H NMR(400MHz,DMSO-d6)δ8.32(s,1H),7.81(s,1H),7.34–7.19(m,2H),7.04–6.96(m,2H),4.78–4.5 3(m,4H),3.79–3.73(m,1H),3.47–3.35(m,1H),3.28–3.10(m,2H),3.08–2.94(m,1H),2.89(s,3H) ,2.37–2.19(m,4H),2.12–1.95(m,6H),1.89(d,J=10.2Hz,2H),1.75(d,J=12.0Hz,2H),1.42–1.31 (m,1H),1.19(q,J=12.6Hz,3H),1.14–1.02(m,6H),1.00(t,J=7.1Hz,1H),0.88(q,J=11.1Hz,2H).

[0266] Example 9: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(3-(1-((trans-4-(ethylsulfonylamino)cyclohexyl)methyl)piperidin-4-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)benzamide

[0267]

[0268] The title compound was prepared by using the corresponding commercial reagents and the product in the above preparation example as raw materials and using a preparation method similar to that in the above Example 6.

[0269] MS (ESI) m / z (M+H) + =643.2.

[0270] 1 H NMR(400MHz,DMSO-d6)δ8.33(s,1H),7.82(s,1H),7.34–7.19(m,2H),7.06–6.95 (m,2H),4.76–4.57(m,4H),3.84–3.70(m,1H),3.46–3.33(m,1H),3.29–3.10(m,2 H),3.05–2.90(m,3H),2.68–2.51(m,4H),2.37–2.27(m,2H),2.08(s,4H),1.86( d,J=10.2Hz,2H),1.75(d,J=12.0Hz,2H),1.53–1.41(m,1H),1.22–0.85(m,15H).

[0271] Example 10: Preparation of N-ethyl-2-(4-(3-(1-(trans-4-(ethylsulfonamido)cyclohexyl)methyl)azetidin-3-ylidene)pyrrolidin-1-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0272]

[0273] Step 1: Preparation of benzyl 3-(1-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)pyrrolidin-3-ylidene)azetidine-1-carboxylate

[0274]

[0275] 2-(4-chloropyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (1060mg, 3.14mmol) and 3-(pyrrolidine-3-ylidene)azetidine-1-carboxylic acid benzyl ester 926mg, 3.14mmol) were dissolved in isopropanol (40mL), heated to 80°C under nitrogen protection and stirred at this temperature for 16 hours. LCMS showed that the raw material reaction was complete, and it was concentrated under reduced pressure. An appropriate amount of water was added to the crude product, extracted with dichloromethane, and the organic phases were combined, washed with 1N hydrochloric acid, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 1.13g of a yellow foamy solid.

[0276] MS (ESI) m / z (M+H) + =560.2.

[0277] Step 2: Preparation of 2-(4-(3-(azetidin-3-ylidene)pyrrolidin-1-yl)pyrimidin-5-oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0278]

[0279] Benzyl 3-(1-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)pyrrolidin-3-ylidene)azetidine-1-carboxylate (1.13 g, 2.02 mmol) was dissolved in trifluoroacetic acid (20 mL), and the reaction system was heated to 60°C for 2 hours. LCMS showed that the raw material was completely reacted, and the product was concentrated under reduced pressure to obtain 965 mg of a dark brown oily product, which was used directly in the next step without purification.

[0280] MS (ESI) m / z (M+H) + =426.2.

[0281] Step 3: Preparation of trans-tert-butyl 4-(3-(1-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)pyrrolidin-3-ylidene)azetidin-1-yl)methyl)cyclohexyl)carbamate

[0282]

[0283] The crude product 2-(4-(3-(azetidin-3-ylidene)pyrrolidin-1-yl)pyrimidine-5-oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide trifluoroacetate (301 mg, 0.56 mmol), (trans-4-formylcyclohexyl)carbamic acid tert-butyl ester (140.2 mg, 0.62 mmol), acetic acid (67.26 mg, 1.12 mmol) and sodium acetate (275.62 mg, 3.36 mmol) were dissolved in methanol (12 mL); after stirring at room temperature for 30 minutes, sodium triacetoxyborohydride (178 mg, 0.84 mmol) was added and the reaction was continued for 2 hours. After LCMS showed that the raw material was completely reacted, the reaction solution was diluted with water, and dichloromethane was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phases were concentrated under reduced pressure to obtain a crude product. The obtained crude product was purified by silica gel column chromatography to obtain 322 mg of a yellow oily liquid.

[0284] MS (ESI) m / z (M+H) + =637.3.

[0285] Step 4: Preparation of 2-(4-(3-(1-(trans-4-aminocyclohexyl)methyl)azetidin-3-ylidene)pyrrolidin-1-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide trifluoroacetate

[0286]

[0287] Trans-4-(3-(1-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)pyrrolidin-3-ylidene)azetidin-1-yl)methyl)cyclohexyl)carbamic acid tert-butyl ester (128 mg, 0.20 mmol) was dissolved in dichloromethane (2 mL), followed by the addition of trifluoroacetic acid (0.6 mL) and stirring at room temperature for 20 minutes. LCMS showed that the reaction of the raw materials was complete, the reaction solution was concentrated under reduced pressure, dichloromethane (15 mL), methanol (2 mL), water (1 mL) and excess solid sodium bicarbonate were added, and the mixture was vigorously stirred at room temperature for 20 minutes. Anhydrous sodium sulfate was added for drying, filtration, and the solvent was drained under reduced pressure to obtain 101.5 mg of a crude light yellow oily liquid, which was directly used in the next step without purification.

[0288] MS (ESI) m / z (M+H) + =537.3.

[0289] Step 5: Preparation of N-ethyl-2-(4-(3-(1-(trans-4-(ethylsulfonamido)cyclohexyl)methyl)azetidin-3-ylidene)pyrrolidin-1-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0290]

[0291] The crude product 2-(4-(3-(1-(trans-4-aminocyclohexyl)methyl)azetidin-3-ylidene)pyrrolidin-1-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (101.5 mg, 0.19 mmol) was dissolved in dichloromethane, followed by the addition of triethylamine (48 mg, 0.47 mmol) and ethylsulfonyl chloride (34 mg, 0.27 mmol). After the addition was completed, the reaction system was stirred at room temperature for 1 hour. LCMS showed that the raw material reaction was complete. The reaction solution was quenched with an appropriate amount of water, and dichloromethane was added for extraction. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the organic phase was concentrated under reduced pressure to obtain a crude product. The obtained crude product was purified by prep-HPLC to obtain 56.6 mg of a white solid.

[0292] MS (ESI) m / z (M+H) + =629.3.

[0293] 1 H NMR(400MHz,DMSO-d6)δ8.35(s,1H),7.85(s,1H),7.25–7.18(m,1H),7.25–7.17(m,1H),6.98(d ,J=8.0Hz,1H),6.95–6.81(m,1H),4.13–3.91(m,2H),3.84–3.71(m,2H),3.70–3.55(m,5H),3.47 –3.36(m,1H),3.28–3.13(m,1H),3.00–2.90(m,3H),2.38(s,2H),2.28(d,J=6.8Hz,2H),1.89–1 .78(m,2H),1.71(d,J=12.8Hz,2H),1.17(t,J=7.2Hz,6H),1.14–1.05(m,8H),1.04–0.84(m,3H).

[0294] Example 11: Preparation of N-ethyl-2-((4-(3-(1-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-yl)azetidin-1-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0295]

[0296] Step 1: Preparation of benzyl 3-(1-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-ylidene)azetidine-1-carboxylate

[0297]

[0298] Benzyl 3-(1-((trans-4-aminocyclohexyl)methyl)pyrrolidine-3-ylidene)azetidine-1-carboxylate (0.35 g, 0.95 mmol) was dissolved in dichloromethane; triethylamine (0.29 g, 2.85 mmol), 4-dimethylaminopyridine (0.023 g, 0.19 mmol) and ethylsulfonyl chloride (0.37 g, 2.85 mmol) were then added. After the addition was completed, the reaction system was stirred at room temperature for 2 hours. LCMS showed that the raw material was completely reacted. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was dissolved in methanol and purified using prep-HPLC to obtain 65 mg of a yellowish jelly.

[0299] MS (ESI) m / z (M+H) + =462.2.

[0300] Step 2: Preparation of N-(trans-4-((3-(azetidin-3-yl)pyrrolidin-1-yl)methyl)cyclohexyl)ethanesulfonamide

[0301]

[0302] Benzyl 3-(1-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)pyrrolidine-3-ylidene)azetidine-1-carboxylate (0.06 g, 0.13 mmol) was dissolved in methanol; palladium carbon was then added, and hydrogen was introduced into the reaction system after the addition was complete, and stirred at room temperature for 1 hour. LCMS showed that the raw materials were completely reacted, and the reaction solution was filtered through diatomaceous earth, and the filtrate was collected and concentrated under reduced pressure to obtain 0.06 g of an off-white solid.

[0303] MS (ESI) m / z (M+H) + =330.2.

[0304] Step 3: Preparation of N-ethyl-2-((4-(3-(1-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)pyrrolidin-3-yl)azetidin-1-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0305]

[0306] N-(trans-4-((3-(azetidin-3-yl)pyrrolidin-1-yl)methyl)cyclohexyl)ethanesulfonamide (0.05 g, 0.15 mmol) was dissolved in an isopropanol solution; 2-[(4-chloropyrimidin-5-yl)oxy]-N-ethyl-5-fluoro-N-propylbenzamide (0.06 g, 0.18 mmol) and triethylamine (0.046 g, 0.45 mmol) were then added. After the addition was completed, the reaction system was heated to 90°C and stirred at this temperature for 5 hours. LCMS showed that the raw materials reacted completely, and the reaction solution was concentrated under reduced pressure to obtain a crude product; the crude product was dissolved in methanol and purified by prep-HPLC to obtain 2 mg of an off-white solid.

[0307] MS (ESI) m / z (M+H) + =631.2.

[0308] 1 H NMR(400MHz,Chloroform-d)δ8.39(s,1H),7.79(s,1H),7.03–6.98(m,2H),6 .72–6.69(m,1H),4.37–4.14(m,2H),3.99–3.76(m,4H),3.52–3.47(m,1H),3 .35–3.32(m,1H),3.22–3.17(m,2H),3.06–3.00(m,2H),2.66–1.86(m,12H), 1.58(s,4H),1.36(t,J=7.4Hz,3H),1.25(t,J=7.0Hz,6H),1.15–0.98(m,5H).

[0309] Example 12: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-((trans-4-((1-methyl-1H-pyrazole)-4-sulfonylamino)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazolinyl]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0310]

[0311] 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (50 mg, 0.096 mmol) was dissolved in acetonitrile (5 mL); cesium carbonate (0.13 g, 0.38 mmol) and 1-methyl-1H-pyrazole-4-sulfonyl chloride (0.026 g, 0.14 mmol) were then added in sequence; after the addition was completed, the reaction system was reacted at 50°C for 0.2 hours. After LCMS showed that the reaction was complete, 10 mL of water was added to the system, and dichloromethane was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by Pre-HPLC to obtain 5.51 mg of the title compound.

[0312] MS (ESI) m / z (M+H) + =667.1.

[0313] 1 H NMR(400MHz,DMSO-d6)δ8.32(s,1H),8.18(s,1H),7.79(s,1H),7.70–7.65(m, 1H),7.37(d,J=6.9Hz,1H),7.31–7.20(m,2H),7.08–7.01(m,1H),4.63–4.54(m ,4H),3.87(s,3H),3.73–3.63(m,5H),3.25–3.06(m,1H),2.87–2.83(m,1H),2. 24(d,J=6.6Hz,2H),2.01–1.98(m,1H),1.71–1.63(m,4H),1.33–0.71(m,14H).

[0314] Example 13: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-((N-methylsulfonamido)amino)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0315]

[0316] 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (100 mg, 0.19 mmol) was dissolved in dichloromethane (15 mL). After adding triethylamine (76.90 mg, 0.76 mmol), N-methylsulfamoyl chloride (36.93 mg, 0.29 mmol) was added dropwise; after the addition was completed, the reaction system was reacted at 25°C for 0.5 hours. After LCMS showed that the reaction was complete, 10 mL of water was added to the system, and dichloromethane was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by Pre-HPLC to obtain 4.28 mg of a white solid.

[0317] MS (ESI) m / z (M+H) + =616.2.

[0318] 1 H NMR(400MHz,DMSO-d6)δ8.32(s,1H),7.79(s,1H),7.38–7.17(m,2H),7.12–6.96(m,1H),6 .77(d,J=7.6Hz,1H),6.53(q,J=5.1Hz,1H),4.76–4.52(m,4H),3.82–3.53(m,5H),3.43–3 .36(m,1H),3.27–3.10(m,2H),2.91–2.74(m,1H),2.42(d,J=5.1Hz,3H),2.35–2.22(m,2H ),2.05–1.94(m,1H),1.88(d,J=12.4Hz,2H),1.71(d,J=12.7Hz,2H),1.30–0.68(m,12H).

[0319] Example 14: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(3-(1-((trans-4-(methylsulfonamido)cyclohexyl)methyl)piperidin-4-yl)azetidin-1-yl)pyrimidin-5-yl)oxy)benzamide

[0320]

[0321] N-ethyl-5-fluoro-N-isopropyl-2-((4-(3-(1-((trans-4-(methylsulfonylamino)cyclohexyl)methyl)piperidin-4-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)benzamide (90 mg, 0.14 mmol) was dissolved in anhydrous methanol (15.0 mL); after replacing hydrogen three times, 10% Pd / C (15 mg, 0.014 mmol) was added at once, and hydrogen was replaced again three times, and the reaction was carried out at room temperature for 1 hour. After LCMS showed that the raw material was completely reacted, it was filtered through diatomaceous earth, washed with anhydrous methanol, and the filtrate was concentrated. The concentrate was purified by HPLC-prep to obtain 27 mg of the title compound.

[0322] MS (ESI) m / z (M+H) + =631.2.

[0323] 1 H NMR(400MHz,Chloroform-d)δ8.38(s,1H),7.77(s,1H),7.07–6.94(m,2H),6.76–6.64(m,1H),4.2 9(d,J=7.5Hz,2H),4.17(t,J=8.9Hz,1H),4.03–3.76(m,3H),3.57–3.41(m,1H),3.40–3.28(m,1H) ,3.29–3.13(m,1H),2.97(s,3H),2.92–2.77(m,2H),2.50–2.34(m,1H),2.22–1.98(m,4H),1.86(d ,J=12.0Hz,4H),1.61(d,J=9.6Hz,2H),1.51–1.36(m,2H),1.32–1.05(m,13H),1.04–0.90(m,2H).

[0324] Example 15: Preparation of N-ethyl-N-isopropyl-2-((4-(1'-((trans-4-(methylsulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0325]

[0326] Weigh 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazamethine]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-N-isopropylbenzamide (66 mg, 0.13 mmol) in a reaction bottle, add dichloromethane (10 mL), and stir evenly under ice-water bath; add triethylamine (52.62 mg, 0.52 mmol), and then add methylsulfonic anhydride (290 mg, 0.17 mmol) in batches. After the addition is completed, continue stirring under ice bath for 10 minutes. After LCMS monitoring, the reaction is complete, water is added, and dichloromethane is extracted. The crude product is obtained by rotary evaporation. The crude product is prepared to obtain 38 mg of the title compound.

[0327] MS (ESI) m / z (M+H) + =583.2.

[0328] 1 H NMR (400MHz, Chloroform-d) δ8.42 (s, 1H), 7.85 (s, 1H), 7.38–7.27 (m, 2H), 7.13 (t, J = 7. 4Hz,1H),6.73(t,J=8.0Hz,1H),4.80–4.47(m,4H),4.19(d,J=7.6Hz,1H),3.93–3.76(m, 4H),3.56–3.43(m,1H),3.40–3.29(m,1H),3.28–3.14(m,1H),2.97(s,3H),2.48–2.37(m ,2H),2.13–1.98(m,2H),1.82(d,J=12.4Hz,2H),1.73–1.50(m,2H),1.38–0.91(m,13H).

[0329] Example 16: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(4-(1-((trans-4-(methylsulfonamido)cyclohexyl)methyl)azetidin-3-ylidene)piperidin-1-yl)pyrimidin-5-yl)oxy)benzamide

[0330]

[0331] The title compound was prepared by using the corresponding commercial reagents and the product in the above preparation example as raw materials and using a preparation method similar to the above Example 10.

[0332] MS (ESI) m / z (M+H) + =629.2.

[0333] 1H NMR(400MHz,DMSO-d6)δ8.40(s,1H),7.89(s,1H),7.35–7.22(m,1H),7.24–7.17(m, 1H),6.95(d,J=7.2Hz,1H),6.93–6.83(m,1H),3.81–3.75(m,1H),3.66(s,8H),3.43– 3.35(m,1H),3.29–3.21(m,1H),3.06–2.95(m,1H),2.88(s,3H),2.27(d,J=6.4Hz,2H ),1.98–1.83(m,6H),1.72(d,J=12.8Hz,2H),1.24–1.06(m,11H),1.03–0.85(m,3H).

[0334] Example 17: Preparation of 2-((4-(1'-(trans-4-((1-((E)-4-(dimethylamino)but-2-enoyl)azetidine)-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0335]

[0336] Step 1: Preparation of tert-butyl 3-(N-(trans-4-((1'-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)methyl)cyclohexyl)sulfamoyl)azetidine-1-carboxylate

[0337] Under ice-water bath conditions, triethylamine (0.22 g, 2.17 mmol) and tert-butyl 3-(chlorosulfonyl)azetidine-1-carboxylate (0.37, 1.446 mmol) were added to a dichloromethane solution of 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (0.43 g, 0.72 mmol). After the addition was completed, the reaction system was continued to react in ice water for 30 minutes. LCMS confirmed that the reaction was complete. After water was added and the layers were separated, the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and column chromatography to obtain 159 mg of a light yellow oily product.

[0338] MS (ESI) m / z (M+H) + =742.3.

[0339] Step 2: Preparation of 2-((4-(1'-(trans-4-(azetidine-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0340]

[0341] At room temperature, trifluoroacetic acid (4.59 g, 40.26 mmol) was added to a dichloromethane solution of tert-butyl 3-(N-(trans-4-((1'-(5-(2-(ethyl(isopropyl)carbamoyl)-4-fluorophenoxy)pyrimidin-4-yl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)methyl)cyclohexyl)sulfamoyl)azetidine-1-carboxylate (0.159 g, 0.21 mmol); after the addition was completed, the reaction system was reacted at room temperature overnight. LCMS confirmed that the reaction was complete, and the product was concentrated under reduced pressure to obtain 0.280 g of a brown oily product, which was used directly in the subsequent reaction without purification.

[0342] MS (ESI) m / z (M+H) + =642.3.

[0343] Step 3: Preparation of 2-((4-(1'-(trans-4-((1-((E)-4-(dimethylamino)but-2-enoyl)azetidine)-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0344]

[0345] To a solution of 2-((4-(1'-(trans-4-(azetidine-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (0.146 g, 0.11 mmol) in N,N-dimethylformamide at room temperature were added (2E)-4-(dimethylamino)but-2-enoic acid (0.028 g, 0.22 mmol), ethyldiisopropylamine (0.043 g, 0.33 mmol) and N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate (0.063 g, 0.17 mmol). After the addition was completed, the reaction system was reacted at room temperature for 30 minutes. LCMS confirmed that the reaction was complete. The product was prepared and purified to obtain 17 mg of a white solid product.

[0346] MS (ESI) m / z (M+H) + =753.3.

[0347] 1 H NMR(400MHz,Chloroform-d)δ8.40(s,1H),7.81(s,1H),7.05–6.97(m,2H),6.88(dt,J=15.5,5.9Hz,1H),6.79 –6.67(m,1H),6.00(d,J=15.4Hz,1H),4.80–4.53(m,5H),4.43(d,J=7.0Hz,2H),4.34(d,J=8.4Hz,1H),4.31–4. 24(m,2H),4.05–3.93(m,1H),3.90–3.79(m,1H),3.74(s,4H),3.58–3.42(m,1H),3.38–3.14(m,2H),3.08(d,J= 5.9Hz,2H),2.37(d,J=6.7Hz,2H),2.26(s,6H),2.00(d,J=12.5Hz,2H),1.90–1.60(m,4H),1.36–0.91(m,11H).

[0348] Example 18: Preparation of 2-((4-(3-(1-(trans-4-((3,3-difluoroazetidine)-1-sulfonamido)cyclohexyl)methyl)piperidin-4-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0349]

[0350] The title compound was prepared by using the corresponding commercial reagents and the product in the above preparation example as raw materials and using a preparation method similar to that in the above Example 6.

[0351] MS (ESI) m / z (M+H) + =706.2.

[0352] 1 H NMR(400MHz,Chloroform-d)δ8.42(s,1H),7.82(s,1H),7.09–6.95(m,2H),6.73(d,J=12.9Hz,1H),4. 82–4.61(m,4H),4.19(t,J=12.0Hz,4H),4.09(s,1H),3.90–3.83(m,1H),3.53–3.48(m,1H),3.35–3.30 (m,1H),3.25–3.19(m,1H),2.34(s,3H),2.20–1.98(m,7H),1.94–1.84(m,2H),1.66–1.55(m,2H),1.4 6–1.36(m,1H),1.26(t,J=7.0Hz,4H),1.16(t,J=6.1Hz,6H),1.10(t,J=7.1Hz,1H),1.04–0.93(m,2H).

[0353] Example 19: Preparation of 2-((4-(3-(1-(trans-4-((3,3-difluoropyrrolidine)-1-sulfonamido)cyclohexyl)methyl)piperidin-4-ylidene)azetidin-1-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0354]

[0355] The title compound was prepared by using the corresponding commercial reagents and the product in the above preparation example as raw materials and using a preparation method similar to that in the above Example 6.

[0356] MS (ESI) m / z (M+H) + =720.3.

[0357] 1H NMR(400MHz,Chloroform-d)δ8.41(s,1H),7.82(s,1H),7.07–6.95(m,2H),6.72(td,J=8.8,4.1Hz,1H),4. 83–4.57(m,4H),4.09(d,J=8.0Hz,1H),3.92–3.79(m,1H),3.60(t,J=12.9Hz,2H),3.50(t,J=7.3Hz,3H),3. 41–3.26(m,1H),3.26–3.10(m,1H),2.47–2.27(m,5H),2.19–1.97(m,7H),1.88(d,J=13.0Hz,2H),1.62(s, 2H),1.51–1.34(m,1H),1.31–1.20(m,4H),1.16(t,J=6.3Hz,6H),1.10(t,J=7.1Hz,1H),1.05–0.92(m,2H).

[0358] Example 20: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-((4-methylphenyl)sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0359]

[0360] Triethylamine (0.036 g, 0.36 mmol) and p-toluenesulfonic anhydride (39.17 mg, 0.12 mmol) were added to a dichloromethane solution of 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (74 mg, 0.12 mmol) at -30°C. After the addition was completed, the reaction system was reacted at room temperature for 5 min. LCMS detected that the reaction was complete, and a saturated sodium bicarbonate aqueous solution was added to quench the reaction. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified to obtain 12 mg of a white solid product.

[0361] MS (ESI) m / z (M+H) + =677.2.

[0362] 1H NMR(400MHz,Chloroform-d)δ8.41(s,1H),7.83(s,1H),7.74(d,J=8.3Hz,2H),7.29(d,J=8.0Hz,2H),7.06–6. 96(m,2H),6.76–6.66(m,1H),4.77–4.53(m,4H),4.39(d,J=7.6Hz,1H),4.12–3.73(m,4H),3.56–3.41(m,1H),3 .39–3.24(m,1H),3.19(q,J=7.1Hz,1H),3.11–2.96(m,1H),2.64–2.47(m,2H),2.43(s,3H),1.84(d,J=12.6Hz ,2H),1.78(d,J=13.0Hz,2H),1.71–1.56(m,5H),1.41–1.19(m,6H),1.18–1.03(m,1H),0.93(q,J=12.5Hz,2H).

[0363] Example 21: N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-((N-(2,2,2-trifluoroethyl)sulfamoyl)amino)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0364] Step 1: Preparation of 2,2,2-trifluoroethylsulfamoyl chloride

[0365]

[0366] At -30°C, N,N-diisopropylethylamine (2.21 g, 17.09 mmol) and sulfonyl chloride (3.84 g, 28.48 mmol) were added to a dichloromethane solution of 2,2,2-trifluoroethylamine (1.128 g, 11.39 mmol); after the addition was completed, the reaction system continued to react at this temperature for 1 hour, and then gradually warmed to room temperature to react overnight. After the reaction was completed, 1N hydrochloric acid was added to quench the reaction, and the organic phase was fully washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 2.5 g of a light brown solid crude product, which was directly used in subsequent reactions without purification.

[0367] Step 2: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-((N-(2,2,2-trifluoroethyl)sulfamoyl)amino)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0368]

[0369] Under ice-water bath conditions, 2,2,2-trifluoroethylsulfamoyl chloride (162.00 mg, 0.82 mmol) and triethylamine (165.95 mg, 1.64 mmol) were added to a dichloromethane solution of 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (52 mg, 0.082 mmol). After the addition was completed, the reaction system was reacted at room temperature for 5 minutes. LCMS confirmed that the reaction was complete. After quenching with water, the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and then purified to obtain 8 mg of a white solid product.

[0370] MS (ESI) m / z (M+H) + =684.2.

[0371] 1 H NMR(400MHz,Chloroform-d)δ8.42(s,1H),7.84(s,1H),7.08–6.91(m,2H),6.77– 6.65(m,1H),5.61–5.32(m,1H),4.81–4.46(m,5H),4.14(s,4H),3.91–3.78(m,1H ),3.64(q,J=8.9Hz,2H),3.56–3.40(m,1H),3.39–3.26(m,1H),3.24–3.11(m,2H) ,2.67(s,2H),2.12(d,J=12.3Hz,2H),1.90(d,J=12.9Hz,2H),1.49–0.94(m,13H).

[0372] Example 22: Preparation of 2-((4-(1'-(trans-4-((N,N-dimethylsulfamoyl)amino)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0373] Step 1: Preparation of trans-4-[(dimethylsulfamoyl)amino]cyclohexane-1-carboxylic acid methyl ester

[0374]

[0375] Trans-4-aminocyclohexane-1-carboxylic acid methyl ester (2g, 12.72mmol) was dissolved in dichloromethane (15mL), followed by the addition of triethylamine (6.44g, 63.6mmol) and N,N-dimethylsulfamoyl chloride (3.65g, 25.44mmol). After the addition was completed, the reaction system was reacted at 25°C for 16 hours. After LCMS showed that the reaction was complete, 100mL of water was added to the system, and dichloromethane was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography to obtain 1.5g of a colorless oily liquid.

[0376] MS (ESI) m / z (M+H) + =265.1.

[0377] Step 2: Preparation of [trans-4-[(dimethylsulfamoyl)amino]cyclohexyl]methanol

[0378]

[0379] Trans-4-[(dimethylsulfamoyl)amino]cyclohexane-1-carboxylic acid methyl ester (1.50 g, 5.67 mmol) was dissolved in tetrahydrofuran (10 mL), the system was cooled to 0°C, and then lithium aluminum hydride (0.26 g, 6.80 mmol) was added; after the addition was completed, the reaction system was reacted at room temperature for 1 hour. After the reaction was completed, LCMS showed that 260 uL of water, 260 uL of 15% sodium hydroxide aqueous solution, and 780 uL of water were added to the system in sequence to quench the reaction, and anhydrous sodium sulfate was added to dry, filtered, and concentrated under reduced pressure to obtain 500 mg of a colorless oily liquid crude product, which was directly used in the next step without purification.

[0380] MS (ESI) m / z (M+H) + =237.1.

[0381] Step 3: Preparation of trans-4-[(dimethylsulfamoyl)amino]cyclohexane-1-carbaldehyde

[0382]

[0383] Dissolve [trans-4-[(dimethylsulfamoyl)amino]cyclohexyl]methanol (500 mg, 2.12 mmol) in dichloromethane (10 mL); then add pyridinium chlorochromate (1.14 g, 5.30 mmol) and 2 g silica gel powder. After the addition is complete, the reaction system is reacted at 25°C for 1 hour. After LCMS shows that the reaction is complete, filter directly and concentrate under reduced pressure to obtain 400 mg of a yellow solid crude product.

[0384] MS (ESI) m / z (M+H) + =235.1.

[0385] Step 4: Preparation of 2-((4-(1'-(trans-4-((N,N-dimethylsulfamoyl)amino)cyclohexyl)methyl)-1',4'-dihydro2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0386]

[0387] 2-((4-(1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (50 mg, 0.12 mmol) was dissolved in dichloromethane (10 mL) / methanol (2 mL); then trans-4-[(dimethylsulfamoyl)amino]cyclohexane-1-carbaldehyde (28.12 mg, 0.12 mmol) was added, and sodium triacetoxyborohydride (0.038 g, 0.18 mmol) was added in batches. After the addition was completed, the reaction system was reacted at 25°C for 0.5 hours. After LCMS monitoring showed that the reaction was complete, 10 mL of water was added to the system, and dichloromethane was extracted three times. The organic phases were combined, backwashed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained crude product was purified by Pre-HPLC to obtain 3.06 mg of a white solid.

[0388] MS (ESI) m / z (M+H) + =630.2.

[0389] 1 H NMR(400MHz,DMSO-d6)δ8.32(s,1H),7.78(s,1H),7.33–7.20(m,2H),7.11– 7.00(m,2H),4.72–4.50(m,4H),3.81–3.57(m,4H),3.45–3.35(m,1H),3.27– 3.06(m,2H),2.97–2.82(m,1H),2.61(s,6H),2.35–2.20(m,2H),2.08–1.94 (m,1H),1.87(d,J=12.5Hz,2H),1.71(d,J=12.9Hz,2H),1.36–0.72(m,13H).

[0390] Example 23: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-((trans-4-(benzenesulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0391]

[0392] The title compound was prepared using the corresponding commercial reagents and the product in the above preparation example as raw materials and a preparation method similar to that in Example 20.

[0393] MS (ESI) m / z (M+H) + =663.2.

[0394] 1 H NMR(400MHz,Chloroform-d)δ8.44(s,1H),7.86(d,J=7.4Hz,2H),7.73(s,1H), 7.58(t,J=7.3Hz,1H),7.53–7.46(m,2H),7.16–7.06(m,1H),7.07–7.00(m,1H), 6.95–6.85(m,1H),5.16–4.74(m,6H),4.35–4.13(m,2H),3.84–3.71(m,1H),3. 44–3.29(m,2H),3.18–2.92(m,3H),1.90(t,J=14.5Hz,4H),1.31–0.96(m,15H).

[0395] Example 24: Preparation of N-ethyl-2-((4-(1'-(trans-4-((N-ethylsulfamoyl)amino)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

[0396]

[0397] Under ice-water bath conditions, 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide trifluoroacetate (61.76 mg, 0.097 mmol) was added to the reaction bottle. Then dichloromethane (5 mL) and triethylamine (19.63 mg, 0.19 mmol) were added, stirred evenly, and N-ethylsulfamoyl chloride (20.89 mg, 0.15 mmol) was slowly added. After the addition was completed, the reaction was allowed to react at room temperature for 10 minutes. LCMS monitored the reaction to be complete, water was added to quench, and dichloromethane was extracted. The organic phases were combined to obtain a crude product, and 11 mg of the product title compound was obtained by preparation.

[0398] MS (ESI) m / z (M+H)+ =630.2.

[0399] 1 H NMR(400MHz,Chloroform-d)δ8.44(s,1H),7.87(s,1H),7.07–6.96(m,2H),6.76–6.62(m,1H),4.88–4.55(m,5H),4.54–4.36(m,1H),4.28–4.07(m,2 H),3.94–3.67(m,1H),3.53–3.40(m,1H),3.40–3.28(m,1H),3.27–2.85(m ,6H),2.14(d,J=12.4Hz,2H),1.98(d,J=12.7Hz,2H),1.29–1.02(m,18H).

[0400] Example 25: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-(pyridine-2-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0401]

[0402] The title compound was prepared using a similar preparation method to that of Example 22 using the corresponding commercial reagents and the product of the above preparation example as raw materials.

[0403] MS (ESI) m / z (M+H) + =664.3.

[0404] 1 H NMR(400MHz, Methanol-d4)δ8.67(d,J=4.7Hz,1H),8.28(s,1H),8.06–7.96(m,2H) ,7.79(s,1H),7.64–7.55(m,1H),7.24–7.12(m,2H),7.03–6.93(m,1H),4.81–4.60 (m,4H),3.95–3.76(m,5H),3.57–3.44(m,1H),3.42–3.33(m,1H),3.27–3.11(m,2H ), 2.40(d,J=6.7Hz,2H),1.85–1.63(m,4H),1.39–1.06(m,12H),1.00–0.82(m,2H).

[0405] Example 26: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-((1-methyl-6-oxo-1,6-dihydropyridine)-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0406] Step 1: Preparation of 5-(benzylthio)-1-methylpyridin-2(1H)-one

[0407]

[0408] At room temperature, 5-bromo-1-methyl-1,2-dihydropyridin-2-one (0.8 g, 4.25 mmol), benzyl mercaptan (1.58 g, 12.75 mmol), tetrakis(dibenzylideneacetone)dipalladium (0.097 g, 0.094 mmol), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (0.190 g, 0.33 mmol), N,N-diisopropylethylamine (1.65 g, 12.75 mmol) and 1,4-dioxane were added to the reaction bottle, and after replacing nitrogen three times, the reaction system was heated to 100°C and reacted at this temperature for 4 hours. LCMS confirmed that the reaction was complete, and the yellow oil product 873 mg was obtained after direct concentration and column chromatography purification.

[0409] MS (ESI) m / z (M+H) + =232.2

[0410] Step 2: Preparation of 1-methyl-6-oxo-1,6-dihydropyridine-3-sulfonyl chloride

[0411]

[0412] Under ice-water bath conditions, 1,3-dichloro-5,5-dimethylhydantoin (0.15 g, 0.78 mmol) was added to an acetonitrile solution of 5-(benzylthio)-1-methyl-1,2-dihydropyridin-2-one (0.12 g, 0.52 mmol), acetic acid (0.26 g, 4.37 mmol) and water (0.50 g, 27.75 mmol), and the mixture was reacted in an ice-water bath for 1 hour. After LCMS confirmed that the reaction was complete, water was added to quench the reaction, and the mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 47 mg of a colorless oily product.

[0413] MS (ESI) m / z (M+H) + =208.0.

[0414] Step 3: Preparation of N-ethyl-5-fluoro-N-isopropyl-2-((4-(1'-(trans-4-((1-methyl-6-oxo-1,6-dihydropyridine)-3-sulfonamido)cyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)benzamide

[0415]

[0416] Under ice-water bath conditions, 1-methyl-6-oxo-1,6-dihydropyridine-3-sulfonyl chloride (33 mg, 0.16 mmol) and triethylamine (23.98 mg, 0.24 mmol) were added to a dichloromethane solution of 2-((4-(1'-((trans-4-aminocyclohexyl)methyl)-1',4'-dihydro2H,2'H-[3,3'-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (50 mg, 0.079 mmol). After the addition was completed, the reaction system was reacted in ice water for 5 minutes. LCMS confirmed that the reaction was complete, and sodium bicarbonate aqueous solution was added to quench the reaction. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure, and then purified by preparative purification to obtain 5 mg of a white solid.

[0417] MS (ESI) m / z (M+H) + =694.3.

[0418] 1H NMR (400MHz, Methanol-d4) δ8.28(s,1H),8.24(d,J=2.7Hz,1H),7.80(s,1H),7.75(dd,J=9 .6,2.5Hz,1H),7.24–7.12(m,2H),7.03–6.91(m,1H),6.59(d,J=9.5Hz,1H),4.79–4.53(m,4 H),4.00–3.76(m,4H),3.59(s,3H),3.56–3.43(m,4H),3.07–2.89(m,1H),2.43(d,J=6.7Hz, 2H), 1.83 (d, J=12.7Hz, 2H), 1.74 (d, J=13.1Hz, 2H), 1.38–1.04 (m, 12H), 1.03–0.84 (m, 2H).

[0419] Example 27: Preparation of 2-((4-(1'-((trans-4-benzamidocyclohexyl)methyl)-1',4'-dihydro-2H,2'H-[3,3'-diazoethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide

[0420]

[0421] Benzoic acid (9.3 mg, 0.076 mmol), ethyldiisopropylamine (14.73 mg, 0.11 mmol) and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)urea hexafluorophosphate (14 mg, 0.038 mmol) were added to a solution of 2-((4-(1′-((trans-4-aminocyclohexyl)methyl)-1′,4′-dihydro-2H,2′H-[3,3′-diazaethylidene]-1(4H)-yl)pyrimidin-5-yl)oxy)-N-ethyl-5-fluoro-N-isopropylbenzamide (24 mg, 0.038 mmol) in N,N-dimethylformamide at room temperature. After the addition was completed, the reaction system was reacted at room temperature for 5 minutes. LCMS confirmed that the reaction was complete, and 5 mg of a white solid was obtained by purification.

[0422] MS (ESI) m / z (M+H) + =627.3.

[0423] 1H NMR(400MHz, Methanol-d4)δ8.29(s,1H),7.85–7.74(m,3H),7.51(t,J=7.3Hz,1H ),7.43(t,J=7.4Hz,2H),7.24–7.13(m,2H),7.04–6.92(m,1H),4.81–4.66(m,4H) ,3.97(s,4H),3.94–3.76(m,2H),3.54–3.47(m,1H),3.43–3.27(m,1H),2.57(d,J =6.7Hz,2H),2.00(d,J=15.7Hz,2H),1.86(d,J=13.0Hz,2H),1.51–1.02(m,15H).

[0424] The following examples can be prepared using corresponding commercial reagents and the products in the aforementioned preparation examples as raw materials, using a preparation method similar to that of Example 22 above.

[0425]

[0426]

[0427]

[0428]

[0429]

[0430] The analytical data of the above described embodiment, including NMR and HPLC data, are as follows:

[0431]

[0432]

[0433]

[0434]

[0435] Experimental Example 1: Menin-MLL protein interaction inhibitory activity test

[0436] Fluorescence Polarization method was used to detect the IC of the test compound inhibiting the Menin-MLL protein interaction 50 value.

[0437] The specific steps are as follows: the compound stock solution (10 mM, DMSO preparation) is diluted with DMSO to 2000, 600, 200, 60, 20, 6, 2, 0.6, 0.2, 0.06 μM. 50 nL of different concentrations of the test compound (10 gradient concentrations) and DMSO solution without the compound (negative control well) are taken by ECHO 665 Series Acoustic Liquid Handlers (BECKMAN Inc.), transferred to a 384-well plate, and centrifuged at 1000 rpm for use. 5 μL Menin (BIORTUS Inc., Cat No. BP9210) is added to each assay well using I.DOT (DISPENDIX Inc.) and incubated at 25°C for 10 minutes. 5 μL FITC-MLL4-43 (Genscrip Inc.) is added to each assay well using I.DOT, centrifuged at 1000 rpm and incubated for 60 minutes. The FP signal was measured and the data were processed using a PHERAstar FSX multifunctional microplate reader (BMG Labtech Inc.).

[0438] Fitting compound IC with nonlinear regression equation 50 :Inhibition%=(negative control well signal-compound well signal) / (negative control well signal-background signal)*100% (background signal is the signal value detected in the assay well containing only 5μL FITC-MLL4-43), with the log value of compound concentration as the X-axis and the percentage inhibition rate (Inhibition%) as the Y-axis, the dose-effect curve was fitted to obtain the IC value of each compound for inhibiting the Menin-MLL protein interaction. 50 The experimental results are shown in Table 1 below:

[0439] Table 1 IC of the compounds of the present invention for inhibiting Menin-MLL protein interaction 50 value

[0440]

[0441] Note: “-” indicates data not tested.

[0442] Conclusion: The above experiments show that the compounds of the present invention have excellent activity in inhibiting the Menin-MLL protein interaction.

[0443] Experimental Example 2: Cell proliferation inhibition experiment (MV-4-11, MOLM-13, HL60 cells)

[0444] Cell plating:

[0445] (1) Remove the cells from the incubator and place them on the operating table. Mix them by gently pipetting and count them using CounterStar.

[0446] (2) Dilute the cells to the required density with fresh complete medium. MV-4-11 (cell source: Nanjing Kebai, catalog number: CBP60522), culture medium: IMDM (HyClone, catalog number: SH30228.01) + 20% FBS (Excell Bio, catalog number: FSP500) + 1% P / S (HyClone, catalog number: SV30010), the plating density is 1×10^4 cells / well, 100μL / well; MOLM-13 (cell source is Nanjing Kebai, catalog number CBP60678) culture medium is RPMI1640 (GIBCO, catalog number: C11875500BT) + 10% FBS + 1% P / S, the plating density is 1×10^3 cells / well, 100μL / well; HL-60 (cell source is Nanjing Kebai, catalog number CBP60517), the culture medium is IMDM + 10% FBS + 1% P / S, the plating density is 1×10^4 cells / well, 100μL / well.

[0447] (3) Use an electric dispenser to pipette 100 μL of each of the above cell suspensions into a 96-well plate.

[0448] Formulated compound:

[0449] (1) First, the stock solution of the compound was diluted with DMSO from 10 mM to 2000, 600, 200, 60, 20, 6, 2, 0.6, and 0 μM, with 0 μM as the control well.

[0450] (2) After thorough mixing, 2.6 μL of the solution was taken out with an electric ejector and added to 257.4 μL of culture medium. The solution was diluted 100 times and the DMSO content was 1%.

[0451] (3) After being thoroughly mixed using a gun mixing mode, the cells plated above were taken out, and two replicate wells were set for each concentration of each compound. 100 μL of the compound diluted in step 2 was added to each of the two replicate wells. The final concentrations of the compounds were: 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0 μM. At this time, each well of the cell culture plate contained 200 μL of culture medium, and the DMSO content was 0.5%. The well containing only 0.5% DMSO (compound concentration was 0) was the control well.

[0452] (4) The cells were returned to the 37°C, 5% CO2 incubator for continued culture. MV-4-11 cells were tested 3 days after treatment with the compound, and MOLM-13 and HL-60 cells were tested 5 days after treatment with the compound.

[0453] CTG test:

[0454] (1) After culturing for a specific period of time, remove the cells and aspirate a portion of the culture medium so that 50 μL of culture medium remains in each well. Use a spray gun to add 50 μL / well of CTG reagent (cell counting-Lite 2.0, Vazyme, DD1101-02).

[0455] (2) Incubate on a shaker at room temperature for 15 min and allow to equilibrate at room temperature for 15 min.

[0456] (3) Detection using a multifunctional ELISA reader.

[0457] Data Analysis:

[0458] (1) Calculate cell viability, Cell viability % = As / Ac×100%. As: test well (culture medium containing cells, CTG, test compound), Ac: control well (culture medium containing cells, CTG, no test compound).

[0459] (2) Using the log value of the compound concentration as the X-axis and the cell viability (Cell viability %) as the Y-axis, a dose-effect curve was fitted to obtain the IC50 value of each compound's cell proliferation inhibitory activity.

[0460] The compound of the present invention has good inhibitory activity on the cell MV-4-11 carrying MLL-r; the IC 50 Greater than 10000nM, indicating that the compound has a selective inhibitory effect on MLL-r cells.

[0461] Table 2 Proliferation inhibition activity of the compounds of the present invention on MV-4-11 cells

[0462]

[0463]

[0464] Example 3: Cardiac safety test of drugs related to hERG potassium channel

[0465] The IC of the test compound on hERG potassium channel inhibition was determined by fluorescence polarization method. 50 value.

[0466] Reagent information: Predictor TM hERG Fluorescence Polarization Assay Kit (Cat. No.: PV5365)

[0467] The specific steps are as follows: the test compound and E-4031 (positive reference compound) are prepared with DMSO to a 20× series concentration, and then the Assay buffer (Predictor TM hERG Fluorescence Polarization Assay Kit) was diluted to a 4× series of concentrations. The starting concentration of the test compound was 100μM, and the starting concentration of E-4031 was 30μM. Take 2.5μL of 6 different concentrations of the test compound solution or 8 different concentrations of E-4031 solution, add them to a 384-well plate, and add 2.5μL Assay buffer to the negative control well. Add 5μL of hERG Membrane solution to each well; 2.5μL of hERG Tracer Red solution (diluted with Assay buffer to a final concentration of 4nM). Incubate at room temperature in the dark for 4h, and use a multifunctional microplate reader with a polarization optical element of 540 / 20-590 / 20nm to measure the fluorescence polarization value of each well.

[0468] The hERG inhibition IC50 value was obtained by performing nonlinear regression (dose response-variable slope) fitting with the log value of compound concentration as the X-axis and the fluorescence polarization value as the Y-axis.

[0469] Table 3 IC inhibition of hERG by the compounds of the present invention 50 value

[0470]

Claims

1. A compound of formula I, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof: in, R is selected from L is selected from a covalent bond or CH 2 ; X 1 , X 2 , X 3 , X 4 Each independently selected from CH 2 or CH 2 CH 2 ; R 1 Selected from C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 3 -C 8 Cycloalkyl, 3-8 membered alicyclic group containing 1-2 atoms selected from N, O, S, 5-10 membered aryl, 5-12 membered heteroaryl, -NR 3 R 4 , a 7-12 membered spirocyclic group containing 0-3 heteroatoms selected from N, O, and S; Optionally, R 1 may be further substituted by one or more selected from halogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, cyano, -COR x 、-NHCO-(C 1 -C 3 wherein Rx is C 1 -C 6 Alkyl, C 2 -C 4 Alkenyl or -CH=CHCH 2 N(CH 3 ) 2 ; R 2 is selected from H or halogen; R 3 Selected from H, C 1 -C 3 Alkyl; R 4 Selected from C 1 -C 3 Alkyl or C 1 -C 3 Haloalkyl; ------ represents possible chemical bonds.

2. A compound of formula II, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof: in, L is selected from a covalent bond or CH 2 ; X 1 , X 2 , X 3 , X 4 Each independently selected from CH 2 or CH 2 CH 2 ; R 1 Selected from C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, C 3 -C 8 Cycloalkyl, 3-8 membered alicyclic group containing 1-2 atoms selected from N, O, S, 5-10 membered aryl, 5-12 membered heteroaryl, -NR 3 R 4 , a 7-12 membered spirocyclic group containing 0-3 heteroatoms selected from N, O, and S; wherein R 1 may be further substituted by one or more selected from halogen, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, cyano, -COR x 、-NHCO-(C 1 -C 3 wherein Rx is C 1 -C 6 Alkyl, C 2 -C 4 Alkenyl or -CH=CHCH 2 N(CH 3 ) 2 ; R 3 Selected from H, C 1 -C 3 alkyl; R 4 Selected from C 1 -C 3 Alkyl or C 1 -C 3 Haloalkyl; ------ represents possible chemical bonds.

3. The compound according to claim 1 or 2, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, L is selected from CH 2 ; X 1 , X 2 , X 3 , X 4 Each independently selected from CH 2 or CH 2 CH 2 ; R 1 Selected from C 1 -C 3 Alkyl, C 3 -C 6 Cycloalkyl, 3-6 membered alicyclic group containing 1-2 atoms selected from N, O, S, 5-10 membered aryl, 5-10 membered heteroaryl, -NR 3 R 4 , a 7-10 membered spirocyclic group containing 0-3 heteroatoms selected from N, O, and S; wherein R 3 Selected from H, C 1 -C 3 Alkyl; R 4 Selected from C 1 -C 3 Alkyl or C 1 -C 3 Haloalkyl; ------ represents possible chemical bonds.

4. The compound according to claim 3, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein X 1 or X 2 CH 2 ; or said X 3 or X 4 CH 2 ; or said X 1 , X 2 , X 3 , X 4 All CH 2 .

5. The compound according to claim 3, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein X 1 , X 2 , X 3 , X 4 All CH 2 ,------represents chemical bonds.

6. The compound according to any one of 1 or 2, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein R 1 Freely selected from 5-10 membered aryl, 5-10 membered heteroaryl or -NR 3 R 4 .

7. The compound according to any one of 1 or 2, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein R 1 is freely selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, azetidinyl, tetrahydropyrrolyl, tetrahydrofuranyl, piperidinyl, morpholinyl, tetrahydropyranyl, pyrazolyl, thiazolyl, thienyl, pyrrolyl, imidazolyl, phenyl, pyridinyl, pyridonyl, pyrimidinyl, quinolyl, isoquinolyl, quinazolinyl, -NHCH 2 CF 3 、-NHCH 3 、-NHCH 2 CH 3 、-N(CH 3 ) 2 、-NCH 3 (CH 2 CH 3 )or 8. The compound according to 7, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, wherein R 1 A group selected from methyl, ethyl, oxetanyl, azetidinyl, morpholinyl, pyrazolyl, thiazolyl, phenyl, pyridinyl, pyridonyl, quinolinyl, -NHCH 2 CF 3 、-NHCH 3 、-NHCH 2 CH 3 、-N(CH 3 ) 2 、-NCH 3 (CH 2 CH 3 ).

9. The compound according to 8, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, R 1 One or more selected from fluorine, chlorine, bromine, iodine, cyano, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, -NHCOCH 3 、-CH=CHCH 2 N(CH 3 ) 2 The group is substituted.

10. The compound according to claim 1, having the following structure:

11. A pharmaceutical composition comprising the compound according to any one of claims 1 to 10, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, and a pharmaceutically acceptable carrier and / or excipient.

12. Use of the compound according to any one of claims 1 to 10, its pharmaceutically acceptable salt, hydrate, isomer, prodrug or mixture thereof, or the pharmaceutical composition according to claim 11 for the preparation of a drug for preventing or treating diseases related to the interaction with Menin-MLL protein.

13. The use according to claim 12 for preparing a method for preventing or treating diseases related to the interaction of Menin-MLL protein, wherein the diseases related to Menin-MLL protein include leukemia, leukemia-related complications, lymphoma, solid tumors or diabetes.

14. The use according to claim 13, wherein the leukemia comprises acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia or myelodysplastic syndrome.

15. The use according to claim 14, wherein the acute myeloid leukemia comprises mixed rearrangement leukemia or nucleoside phosphorylation enzyme 1 (NPM1) mutation leukemia.

16. The use according to claim 13, wherein the leukemia-related complications include leukemic meningitis.

17. The use according to claim 13, wherein the solid tumors include pancreatic cancer, colon cancer, liver cancer, glioblastoma, lung cancer, breast cancer, and prostate cancer.

18. The use according to claim 13, wherein the lymphoma comprises Hodgkin's lymphoma, non-Hodgkin's lymphoma, plasma cell tumor, multiple myeloma, cutaneous T-cell lymphoma, and lymphoid tumor.

Citation Information

Cited By

  • Azacycloalkane Menin-MLL protein inhibitor as well as pharmaceutical composition and application thereof

    CN122010910A

  • A diazacyclobutene drug intermediate and its industrial synthesis method

    CN123106499A

  • Biazacycloalkane menin-MLL protein inhibitors, pharmaceutical composition thereof and use thereof

    WO2026098672A1